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CHAPTER I
INTRODUCTION
Septic shock induced by invading gram negative bacteria {GNB) is a
significant concern of modern day health professionals {68,169,172,286).
The prevalent use of antibiotics, invasive life support systems,
catheteriz~tions,

immunosuppressive therapy, and organ transplants in

medical centers have caused the number of GNB-induced cases of septic
shock to escalate (9,70,80,105,146,270,281,286,288).

Indeed, septic

shock with concomitant hemodynamic, metabolic and neuro-endocrine
alterations has been called the ultimate disease of meuical progress
{70).

Prior to the 1920's, less than 100 cases of GNB-induced shock were

reported (72).

In the U.S. today, approximately 1% of hospital

admissions develop GNB-induced sepsis, with more than 100,000 resultant
deaths yearly (68,170).
The chain of events responsible for the lethal demise of the septic
host is complex and as yet unresolved.

One long-standing, major

pathogenetic theory emphasizes that endotoxin (ETX), a lipopolysaccharide
complex isolated from the cell wall of GNB, is the direct causative agent
for the morbidity and mortality of GNB induced septic shock{l07,286,288).
Indeed, ETX treated animals as well as human subjects demonstrate Lhe
septic symptoms such as fever, cation shifts, increased white blood cell
counts, mu.

~le

wasting, acute phase protein synthesis, decreased

lipogenesis, hyperinsulinemia, and glucose dyshomeostasis (73,106,107

1

2

243,283) which are associated with septic shock, multiple systems organ
failure and eventual mortality.
In recent years an alternate, novel theory of septic shock pathogenasis proposes that ETX elicits all its pathophysiological effects by
stimulating cells of the immune system to release septic mediators.

In

particular, macrophages activated either by GNB or their constituent ETX
release a number of mediators which are now recognized as key components
in the pathophysiology of septic shock, such as prostaglandins, leukotrienes, platelet-activating factor, and the monokines tumor necrosis
factor (TNF) and interleukin 1 (IL-1) (75,180,220).
Of all the pathophysiological changes which occur during septic
shock, altered substrate metabolism may be the eventual critical
component in the demise of the septic host (17,177).

During infection

and tissue injury cells tend to rely heavily on glucose for the energy
required to function and survive.

Because the liver is the major site

for systemic glucose production, alterations in hepatic glucoregulation
may produce the changes in circulating plasma glucose concentrations,
which in turn impact detrimentally on cell function.

In particular,

monokines released from the liver macrophages, i.e. Kupffer cells, in
response to invading GNB and ETX (64) may be critical in the glucose
alterations of septic shock.
Therefore, the overall purpose of this dissertation is to contribute
fundamental

}W

knowledge regarding the role of the mononuclear phagocyte

system in the pathogenesis of gram negative septic shock.

The major

focus is on the role of TNF in the pathophysiology of lethal endotoxicosis in conscious rats.

The specific aims include:

1) an in vivo

3

evaluation of TNF as a mediator of the endotoxic syndrome including
mortality, hemodynamic, metabolic, and neuro-endocrine aspects; 2) an in
vivo
.............. examination of the pathophysiological changes induced by cotreatment with TNF and ETX; and 3) an in vitro evaluation of the direct
glucoregulatory effects of TNF on hepatic carbohydrate metabolism using
isolated perfused rat livers and jsolated liver parenchymal cells.

CHAPTER II
REVIEY OF RELATED LITERATURE
The relat-ed literature published up to June 1, 1988 was revie•.red in
this dissertation.

Because of the extensive interest in the biological

activities of TNF, the author realizes that numerous relevant papers have
been published more recently.

Yhen considered to be of tte utmost

importance to the interpretation of the data, a few of the most recent
papers have been included in this dissertation.
A.

HISTORY OF TUMOR NECROSIS FACTOR
For years,

physicis~s

noted that some cancer patients who

be~ame

infected subsequently demonstrated significant tumor regression.
Intrigued by these findings, Coley devoted his career to the treatment
of cancer patients with bacterial products.

After one of his cancer

patients recovered from a neck sarcoma after 2 attacks of erysipelas
(49), Coley induced erysipelas in his cancer patients as a means of
treatment (50).

However, Coley quickly realized that infecting

pat~ents

already compromised by the cancerous insult frequently led to a fatal
outcome.

Therefore, Coley implemented a filter sterilized preparation of

the soluble toxins produced by Streptococcus erysipelas and Bacillus
prodigiosus as a means of cancer treatment rather than live bacteria.

In

1894, Coley reported the successful use of "Coley's Mixed Toxins" in the
treatment of a patient with inoperable abdomi '.lal walJ. sarc. 'ma (51).

An

extensive report of Coley's works and mixed toxin preparations was later
published by his daughter in 1953 (184).
4

5

In 1942, Zahl, et al. (287), suggested that the tumor necrotizing
agent produced by gram negative bacteria might be identical with a
polypeptide component of the endotoxin antigen (287).

Shear, et al.

(233), had isolated the necrotizing agent from Serratia marcescens
cultures and determined it to be a polysaccharide-rich fraction; submicrogram quantities produced significant tumor necrosis within a few
hours (232).
In 1962, O'Malley, et al. (189), demonstrated that serum from normal
mice injected with Serratia marcescens polysaccharide had dose and time
dependent tumor necrotizing activity when injected into recipient tumor
bearing mice.

In 1975, Carswell, et al. (40), further examined the

hypothesis that a serum factor was involved in the bacteria-evoked tumor
necrotizing activity.

Mice were pretreated with the macrophage stimulant

bacillus Calmette-Guerin (BCG) 14 days prior to challenge with lipopolysaccharide (LPS).

Within a few hours after LPS challenge, donor mice

demonstrated significant tumor regressing activity.

Carswell,~.,

suggested that lipopolysaccharide acted indirectly to cause tumor
regression by stimulating the release of a necrotizing substance from the
macrophages which they called "tumor necrosis factor."
Concurrently, a group of investigators at Rockefeller University was
examining the mechanism responsible for the severe cachexia associated
with chronic infection.

In 1980, Rouzer and Cerami (215) reported that

rabbits infected with the parasite Trypanosoma brucei becan.
spite of elevated circulating levels of triglycerides.

cachectic in

In order to

examine this further, Kawakami and Cerami utilized an ETX model of
infection rather than a parasitic model (119).

They demonstrated a

6

dramatic decrease in lipoprotein lipase (LPL) activity and a concomitant
increase in serum triglyceride levels 16 hours after ETX challenge.

A

similar response was produced in endotoxin-resistant mice administered
serum from endotoxin-sensitive mice 2 hours after an ETX challenge.
Thus, a serum factor present in the donor blood was associated with the
hyperlipemia produced during bacterial or parasitic infection.

They

determined that peritoneal exudate cells produced a LPL-suppressing
factor after stimulation with ETX.
Kawakami, et al. (121), continued to study the LPL-suppressing
factor using

th~

well-defined pre-adipocyte cell line, 3T3-Ll (121).

Media isolated from peritoneal exudate cells stimulated in vitro with ETX
markedly suppressed LPL activity in 3T3-Ll cells.

Beutler, et al. (25),

purified this cachexia-inducing factor and named it "cachectin". Beutler,
et al. (23), subsequently determined that the macrophage-released
mediators, "cachectin" and "tumor necrosis factor," were one in the same.
B.

BIOCHEMISTRY OF TUMOR NECROSIS FACTOR
1.

Isolation and structure
Studies reported between 1976 and 1981 used serum from mice and

rabbits treated in the manner described by Carswell, et al. (40), as a
source for TNF.

TNF isolated from mouse and rabbit sera was a protein

with a molecular weight of 67,000-150,000 daltons, as determined by
polyacrylamide gel electrophoresis (94,167,216) or 39,000-225,000 daltons
when determined by gel filtration (132,157,167,168,216).

TNF dissociated

to a smaller molecular weight form under denaturing conditions, thus
indicating that TNF may exist as an oligomer under natural conditions
(94,157).

Mouse TNF was a glycoprotein (94,132) with a pI-4.8 (157),

7

whereas rabbit TNF was a protein with little or no carbohydrate moieties
and a pI-5.l (167,168,216).
temperatures~

Both mouse and rabbit TNF were labile at

70°C (94,132,167,168,216)

Fransen, et al. (85) and Pennica, et al. (197) constructed the
cDNA for mouse TNF by isolating the mRNA from the monocytic cell line
PU5.l.8.

The amino acid sequence predicted from the cDNA indicated that

mouse TNF is synthesized as a pre-TNF protein, with a 79 amino acid presequence attached to the 156 amino acid protein.

When produced in vivo,

TNF is glycosylated at the specific amino acid site predicted by the cDNA
(197).

The amino acid sequence for rabbit TNF also was determined from

its corresponding cDNA. ·Like mouse TNF, rabbit TNF is synthesized as a
pre-TNF protein, with an 80 amino acid pre-sequence followed by a 154
amino acid protein (112).
Human TNF, isolated from human peripheral blood monocytes and
monocytic cell lines, was determined initially to be a protein with a
molecular weight of 40,000-70,000 daltons by gel filtration.

Similar to

mouse and rabbit TNF, human TNF was pH and temperature sensitive
(7,188,280).

Aggarwal, et al. (7) suggested that TNF existed as a dimer

or trimer under natural conditions which dissociated into a monomer of
17,000 daltons under denaturing conditions.

Pennica, et al. (198) and

Wang, et al. (273) described the cDNA cloning for human TNF and its
expression

in~.

coli to produce recombinant TNF.

TNF is synthesized as

a larger precursor molecule, with a leader sequence of 76 amino acids
attached to the 157 amino acid protein containing 2 cysteine residues, no
glycosylation sites, and a

pI~5.3

(7,198,273).

8

TNF is a highly conserved protein, as illustrated by the homology
between mouse, rabbit, and human TNF.

Mouse and human TNF have

approximately 80% homology in amino acid sequence (160,197).

Similarly,

Ito, et al. (112) reported an 81.9% homology in amino acid sequence
between human and rabbit TNF (112).

A 33 nucleotide sequence is totally

conserved in the 3'-untranslated region of mouse and human TNF mRNA (39).
This 33 nucleotide sequence is composed entirely of A and T residues in a
repeating octamer of TTATTTAT.

The human gene encoding for TNF was

identified (234) and determined (239) to be encoded within the major
histocompatibility complex on chromosome 6 and to contain 3 intrans
(111,160).
Whether the active form of TNF is a monomer or trimer is still
under investigation.

Smith,

~·

(237) reported a 5.5 fold lower

binding activity of the TNF monomer than that of the TNF trimer.
dissociation constants also differed substantially:
trimer and Ko-70 nM for the monomer.

The

the Ko=90 pM for the

The molecular form of TNF in

solution was dependent on its concentration:

as the concentration of TNF

in solution decreased, TNF dissociated into either a monomer or dimer
dependent upon the pH in the solution (183).

The structure of TNF, as

determined by Davies, et al. (60), is a non-helical P-sheet rich
structure which may be a noncovalently associated oligomer.
2.

Source
Since Carswell's suggestion that macrophages were the cellular

source of TNF (40), in vivo studies by Green, et al. (95) and Mannel, et
al. (159) indirectly supported that theory.

Green observed that the

concentration of TNF in the serum of BCG-primed, endotoxin challenged

9

mice correlated with a measurable hepatosplenomegaly and suggested that
the macrophage-rich tissues were the source of serum TNF.

Mannel, et al.

(159) determined that the host's ability to necrotize an invading tumor
after an endotoxin challenge was dependent on the ETX responsiveness of
bone marrow cells.
In vitro studies with isolated macrophages demonstrated directly
that macrophages were the primary site for synthesis and release of TNF.
TNF production by mouse, rat, rabbit, and human macrophages was
stimulated by ETX, BCG, Q. parvum, zymosan, and poke weed mitogen
(55,81,155,158,165,188).

Stimulated macrophages synthesized and released

more TNF than unstimulated, plastic adhered macrophages (162,164).

TNF

is not stored intracellulaFly; it is produced in response to macrophage
activation (163).

Cycloheximide and actinomycin D treatment inhibited

TNF production in vitro (81,163,164,165), therefore substantiating that
TNF is not stored intracellularly but is produced in response to
macrophage activation.

Studies with rabbit antiserum specific for serum

TNF established that TNF produced in vitro by isolated macrophages was
the same as TNF produced in vivo (155,158),

Macrophage cell lines also

produce TNF in vitro (25,133) after activation.
Although macrophages are the primary cellular source of TNF,
Peters, et al. (201) and Cuturi,

~.

production by natural killer cells.
reported

1

(56) demonstrated detectable TNF

Christmas, et al. (47), however,

ittle or no TNF production by natural killer cells, but

significant production by T lymphocytes after stimulation with phytohaemagglutinin (PHA).

T lymphocytes stimulated with phorbol-12,13-di-

butyrate, A23187, PHA, anti-T3 + IL-2, or PMA produced significant

10
quantities of TNF (56,241,246).

The ca++ -ionophore A23187 potentiated

TNF production by T cells stimulated with phorbol-12,13-dibutyrate (56)
and anti-CD3 monoclonal antibody (246).

Additionally, epithelial tumor

cell lines provoked with cycloheximide produced TNF (240).
3.

Production and regulation
As briefly discussed in section 2, TNF is produced primarily by

activated macrophages.

Agents that enhanced the reticuloendothelial

system, such as bacillus Calmette-Guerin (40,108,222), Corynebacterium
granulosum (40), Corynebacterium parvum (40,90,95,108,223), zymosan (40),
Propionibacterium

~

(100), Listeria monocytogenes (101), and

thioglycollate (90,91) significantly increased TNF production after an
endotoxin challenge (83,90,101).

Howe7er, endotoxin alone stimulated

significant TNF production both in vivo (83,90) and in vitro (25,90,131).
The lipid A moiety of endotoxin and not the polysaccharide-rich fraction
was responsible for the stimulatory effect (100).

TNF also is produced in vitro by monocytic cell lines such as HL60 and U937 (6,102,198).

Stimulation with either PMA, interferon-gamma

(IFN-7), interferon-alpha (IFN-a), lymphotoxin (TNF p) or TNF produced a
transient increase in TNF m.RNA which is inhibited with the protein kinase
C inhibitor, H7 (102).

As quickly as 20 minutes after activation,

measurable levels of TNF m.RNA were produced (221).

The

stimul~s

for TNF

production must be continuously present during the incubation in order
for TNF production to co1

~ ~.nue:

for exAmple, removal of ETX at any time

during the incubation period immediately halted TNF production (91).

TNF production is enhanced by IFN-7 and inhibited by prostaglandin
E2 and dexamethasone.

IFN-7 'primes' the macrophages so that a greater
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quantitiy of TNF is produced after ETX stimulation (27,36,91,92).

IFN-1

increased TNF production by acting at both the transcriptional (27,36,52)
and post-transcriptional (27,36) levels.

Incubation with cycloheximide

increased the transcription of TNF mRNA 12 fold in response to stimulation with phorbol ester (221), whereas transcription of TNF mRNA was
increased 50 fold in peritoneal macrophages incubated with cycloheximide
plus IFN-1 (52).
Prostaglandin E2 and dexamethasone act in a similar manner to
decrease TNF production.

Kunkel, et al. (135,136) reported a dose

dependent decrease in endotoxin-induced TNF production by prostaglandin
E2:

prostaglandin E2 at concentrations greater than 10 nM decreased TNF

production by 80%.

Prostaglandin E2 acted primarily to decrease the

transcription of TNF mRNA (135).

Pretreatment with dexamethasone

significantly inhibits TNF production:

TNF production is inhibited 50-

90% after pretreatment with dexamethasone (266,267).

Just as IFN-7 and

prostaglandin E2, dexamethasone acted at both the transcriptional and
post-transcriptional levels to decrease TNF production (24).
As reported by Beutler, et al. (25), TNF is a major macrophage
secretory product, comprising 1-5% of total protein synthesized by
activated macrophages.

Within 15 minutes of macrophage activation,

measurable levels of TNF are produced (22,28,90).

Peak serum TNF levels

are reached approximately 90 minutes after endotoxin injection in humans
(103,174,175), mice (90,95), rats (266), "abbits (28,Hil), and baboons
(103).

Similar results are observed for TNF production by activated

macrophages in vitro (102).

The half-life for TNF ranges from 0.5 to 27
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minutes (28,31,82,161,266), and the kidneys are important in TNF
breakdown and elimination (200).
4.

Receptor
As documented in table 1, receptors £or TNF are present on a

number of different cell types.
ranges from 230-11,000, with

Ko

The number of receptor sites per cell
values of 2.6 x lo-13 - 0.8 x lo-9 M.

TNF binding is saturable and dependent on experimental conditions, such
as dose, temperature, and time.

After binding to its receptor, TNF is

internalized and degraded intracellularly (14,110,258).

The presence of

TNF receptors, alone, is insufficient to predict whether the
respond to TNF (134,244,258).

cell will

Beutler, et al. (25) determined that TNF

binding to as few as 5% of the receptors will produce a significant
cellular response.
In vivo binding sites for TNF were determined by Beutler, et al.
(28) after an i.v. bolus injection of 125!-TNF.

Thirty-one percent of

the radiolabeled TNF was recovered in the liver, approximately 30% in the
skin, 9 and 8% in the G.I. tract and kidneys, respectively.
found in the lungs and 1% was found in the spleen.

Only 2% was

When expressed as a

percentage of the average counts found per gram of tissue wet weight, the
liver and kidneys possessed the greatest degree of radioactivity, followed by the lungs, spleen, and skin.
The structure of the TNF receptor was examined using radiolabeled
TNF covalently cross-linked to its receptor prior to

is~~ation.

Tsujimoto, et al. (256) and Scheurich, et al. (226) determined that the
TNF-receptor complex had a molecular weight of 100 kda and 76 kda,
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TABLE 1

TUM.OR NECROSIS FACTOR RECEPTORS
CEIJ.. TYPE

RECEPTOR NUMBER

Ko"""CM=).___

REFERENCE

(sites/cell)

3T3-Ll ADIPOCYTES

10,000

o.33 x io-9

G2 MUSCLE CELLS

10,000

o.33 x io-9

L-M

1100

3 x 10-1 2

L929

770

3 x io-12

3T3A31

1050

2.5 x io-1 2

J774.l

1100

3 x io- 12

GPAE

1500

3

He, La

6000

2 x 10·10

JURKATT

1100

2.5 x 10·10

L929

2200

6.1 x io-10

Tsuj imoto et.

FS-4

7500

3.2 x 10-10

al., (258)

(HUMAN PERIPHERAL

230

2.6 x lo-13

Imamura et.al.

BLOOD MONOCYTES)

3800

i. s x 10-10

ME-180

2250

o.31 x lo-9

Wl-38

2172

0.22

T24

1512

o.2s x lo-9

PMN

6000

1. 37 x lo-9

x

Beutler et.al.

(25)
Kull et.al.

(134)

io- 1 2

x

lo-9

Haglioni et.al.

(14)

(110)

Sugarman.et.al.

(244)

Shalaby et.al.

(231)
MCF-7

2500

0.13 x io-9

4000

o.s

x

lo-9

Creasey et.al.

(54)
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respectively.

Kull, et al. (134) observed 2 bands of autoradiographic

activity; a prominent band at 95 kda and a second band at 75kda.
bands of activity were isolated by Creasey,

~.

weights of 138 kda, 90 kda, 75 kda, and 54 kda.

Four

(54) with molecular

Three of the four

components, 90 kda, 75 kda, and 54 kda, were present on cells whether
they did or did not respond to the cytotoxic, proliferative, or
stimulatory effects of 'l'NF.

The 138 kda component was determined to

exist only on cell lines that were sensitive to the cytotoxic effects of
TNF.

The 350 kda globular protein demonstrated by Smith, et al. (238)

corresponds to the molecular weight of the TNF receptor when all four
subunits are present.
TNF receptor binding is significantly influenced by agents such as
interferon-7, conconavalin A (Con A), and protein kinase G activators.
Interferon-7 and Con A significantly enhance TNF receptor binding.
Aggarwal, et al. (5), Tsujimoto, et al. (257,259) and Ruggiero, et al.
(217) demonstrated a transient 30-300% increase in TNF receptor binding
with no change in receptor affinity after treatment with IFN-7.

Inter-

feron-7 increased TNF receptor binding by increasing receptor synthesis,
since treatment with actinomycin D blocked the effect (217).

The

stimulatory effect of IFN-7 was dose, temperature, and time dependent,
and for some cell lines, was influenced by type I interferon (257,259).
Con A treatment, on the other hand, significantly increased receptor
binding without increasing TNF receptor synthesis or affinity (8).

Con A

significantly increased receptor binding by decreasing receptor internalization and degradation.
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TNF receptor binding is significantly reduced by treatment with
protein kinase C activators.

Agents such as

4~-phorbol

12-myristate 13-

acetate (PMA), l-oleoyl-2-acetyl glycerol (OAG), and ca++ ionophore
A23187 significantly reduced TNF receptor binding (4,109,115,262).
Receptor binding decreased from 50-95% (4,262) due to either a decrease
in receptor affinity (115,262) or a redistribution of TNF receptors
(4,109).

Pretreatment with the protein kinase C inhibitors, H7 or

staurosporine (115,262), significantly reduced the inhibitory effect of
PMA on TNF receptor binding.

Furthermore, interleukin 1 also decreased

TNF receptor binding (109).
C.

EFFECTS OF TUMOR NECROSIS FACTOR AT THE CELLULAR LEVEL
1.

Hematocrit and white blood cell counts
Depending on the model, a single injection of TNF can elicit

either no change (253) or an increase in hematocrit (16,210,249).
Tracey, et al. (253) reported no significant change in hematocrit for as
long as 3 hours after infusion of non-lethal (10 µg/kg) or lethal (100
µg/ml) doses of TNF, as demonstrated using anesthetized beagle dogs.
However, a significant hemoconcentration was observed in mice (16,210)
and rats (249) after a single injection of TNF.

Mice injected with 5 and

10 µg of TNF had a significant hemoconcentration response by 2 hours:
hematocrit increased significantly from a control value of 38.6 to 46.6
and 48.8%, respectively (210).

After injection of a larger dose of TNF,

3 mg/kg, an increase in hematocrit of 150% relative to control mice was
produced by 6 hours (16).

Similar observations were reported by Tracey,

et al. (249) after a lethal injection of TNF in rats (249).
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After repeated doses of TNF, a significant hemodilution response
is observed in both humans and rats.

Cancer patients administered TNF

twice weekly for 4 weeks demonstrated a significant drop in hemoglobin
content from 12 to 9.3 g/dl (31).

Tracey, et al. (254) reported a

similar observation in rats given TNF twice daily for 8 days:

hematocrit

dropped from a control value of 45% to approximately 28% by the eighth
day.

Accounting for the drop in hematocrit was the significant de-

pression in red blood cell mass and hemoglobin content (254).
The effect of TNF on white blood cell (WBC) counts was time and
model dependent.

Remick, et al. (211) observed in mice a transient

initial lymphocytosis 15-30 minutes after TNF injection which was
followed by a rapid drop in lymphocyte number.

By 2 hours, a marked

lymphopenia was observed in mice given TNF, with the relative as well as
the absolute number of lymphocytes decreasing from 77 to 21% and from 294
x 104 to 62 x 104 cell/ml, respectively (210).

In anesthetized beagle

dogs, however, Tracey, et al. (253) reported a significant drop in white
blood cell count within 15 minutes after lethal infusion of TNF; white
blood cell count dropped from a control value of 6.0 to 1.6 cells/mm3 in
TNF treated dogs.

In human cancer patients, a 50% decrease in lymphocyte

concentration was observed 4 hours after TNF injection (31).

When TNF

was given repeatedly to rats, a marked leukocytosis was observed.

Tracey

reported that the number of leukocytes increased from a pre-injection
value

- 5.8 x lo-3 cells/mm3 to 14.7 x lo-3 cells/mm3 (254).
Concomitant with the decrease in lymphocytes was a marked increase

in neutrophils.

Ulich, et al. (261) and Remick, et al. (211) reported a

transient initial drop in neutrophil number within the first 30 minutes
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after TNF injection which was followed by a significant increase between
1 and 2 hours post-injection.

Remick, et al. (211) reported both a

relative and absolute increase in neutrophils:

the percentage increased

from 21 to 79%, while the absolute number of neutrophils increased from
75 x 104 to 237 x 104 cells/ml (210).

Blick reported a significant

increase in granulocyte number 4 hours after the administration of TNF:
granulocytes increased from a control value of 4.8 x 10 3 cells/mm3 to
7.03 x 103 cells/mm3.

However, the neutrophilia was a transient

response:

neutrophil counts returned back to control values by 24 hours

(31,261).

The neutrophilia induced by TNF was caused by the de-

margination of mature PMNs and the influx of immature cells from the bone
marrow (210,211).
These studies demonstrated that the hematocrit and white blood
cell count changes induced by TNF were dependent on the model used and
the time of measurement.
2.

Polymorphonuclear neutrophils
PMNs' function in cell-mediated immunity is vital in host defense.

TNF increases the bactericidal activity of PMNs through:

1) enhancement

of phagocytic activity; 2) increased superoxide anion production; and 3)
increased chemotaxis to the site of infection.
One way by which TNF increased the bactericidal activity of PMNs
was by augmenting their phagocytic activity.
Shalaby, et al. (230)
activity of PMNs.

Blanchard, et al. (30) and

:amined the influence of TNF on the phagocytic

TNF dose dependently (10-1000 U/ml) enhanced the

bactericidal activity of PMNs for Legionella pneumophilia in vitro (30).
Similarly, TNF pre-treatment, 10,000-50,000 U/rat for 2-4 hours,
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increased the removal of 1· pneumophilia bacteria from infected lungs and
subsequently protected 50% of the animals from the lethal effects of 1.
Rneumophilia (30).
A second means by which TNF enhances bactericidal function of PMNs
is by augmenting superoxide anion production.

Larrick, et al. (140) and

Tsujimoto, et al. (260) demonstrated the direct stimulatory effect of TNF
on PMN superoxide anion production.

Larrick, et al., reported a 2 to 3

fold increase in superoxide production by PMNs after incubation with
0.01-1 µg/ml TNF for 15 minutes.

Tsujimoto, et al., reported maximal

stimulation of superoxide production after incubation for 90 minutes with
10-9 M TNF.

Inhibition of intracellular ca++ mobilization significantly

suppressed superoxide anion production in response to TNF (260).

Others

have reported TNF to be either a weak direct stimulus (129) or to have no
direct effect (10,20) on superoxide anion production.
In the presence of PMN activators such as zymosan or f-methionylleucyl-phenylalanine (FMLP), PMN superoxide production is greatly enhanced by TNF.

Klebanoff, et al. (129) observed a 10 fold increase in

superoxide production stimulated by unopsonized zymosan plus 50 U of TNF
over the amount produced after stimulation with TNF alone (129).

Pre-

treatment with TNF for only 5-10 minutes increased, 0.5 to 18 fold,
superoxide anion production stimulated by FMLP (10,20).

Atkinson

reported that TNF enhanced superoxide anion production in response to
FMLP stimulation by changing all the i.;;:..p binding sites to high affinity
sites:

the total number of receptors remained unchanged but the binding

affinity increased (10).
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Thirdly, TNF stimulates PMN migration to the sites of inflammation.

Ming, et al. (176) demonstrated in vitro the PMN migratory

response to a TNF concentration gradient.

In the presence of a positive

TNF concentration gradient of 10-10 3 U/ml, PMN migration across a polycarbonate filter was significant.
similar response in vivo:

Cybulsky, et al. (58) demonstrated a

intradermal injections of lo·ll -10·10 moles

of TNF/injection site induced significant PMN migration to the injection
site within 1-1.5 hours.

TNF also increased the adherence properties of

PMNs as a means of enhancing their localization to the site of infection.
Seow, et al. (229) demonstrated a significant increase in PMN adherence
as early as 5 minutes after treatment with 500 U/ml TNF.

Gamble, et al.

(87) demonstrated enhanced PMN adherence to human umbilical vein

endo~

thelial cells (HUVE) after treatment with TNF for as little as 5 minutes.
PMNs' rapid response to TNF stimulation is important for the quick
mobilization of PMNs to a site of infection.
3.

Fibroblasts
TNF significantly influences fibroblast function in a number of

ways.

For instance, TNF significantly enhances fibroblast proliferation

in a dose dependent manner.

After screening 39 human and mouse cell

lines, Sugarman, et al. (244) demonstrated a dose dependent mitogenic
effect of TNF on the human lung fibroblast cell line, WI-38:

TNF at

doses of 5- 5000 U/ml significantly increased cell number after 48-72
hours of incubation.

Vilcek, et al. (265) reported tl-

growth enhancing

effect of lo-10.10·13 M TNF on the human diploid fibroblast cell line,
FS-4.

TNF stimulated cell proliferation even in contact inhibited FS-4

cells when 5% fetal calf serum was present in the incubation medium.
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-.
in the presence of additional serum-derived growth factors, TNF's
~,.us,
mitogenic activity overrides growth inhibitory conditions.
The mitogenic response resulted from either growth factor or cfos and c-myc mRNA production by fibroblasts in response to TNF stimulation.

For instance, when protein synthesis was inhibited with 0.1

mg/ml cycloheximide, TNF at a dose of 10 ng/ml was cytotoxic for human
diploid fibroblasts (128).

However, pretreatment for 4 hours with TNF

completely protected fibroblasts from the cytotoxicity observed after TNF
plus cycloheximide co-treatment.

This protective effect may be at-

tributed to two proteins of 36,000 and 42,000 molecular weights that are
synthesized in response to TNF (128), although as many as nine proteins
were determined after incubation with 1000 U/ml TNF for 24 hours (19).
The induction of c-fos and c-myc oncogene expression may be more
important in the mitogenic response to TNF stimulation than protein
production.

Lin and Vilcek (149) reported that incubation with 30 ng/ml

TNF for 20 minute induced a transient increase in c-fos and c-myc mRNA
expression, with peak concentrations by 30 minutes followed by a rapid
decline to control levels by 60 minutes.
TNF also stimulates the synthesis and release of prostaglandin E2
and collagenase by cultured fibroblasts.

Human synovial cells and dermal

fibroblasts incubated for 3 days with 3.0 nM TNF maximally produced
prostaglandin E2 and collagenase, as described by Dayer, et al. (61).
Normal lung fibroblasts stimulated for 3 days with 20 ng/ml TNF demonstrated an increased synthesis of glycosaminoglycan (69):

Elias et al.

reported an 159% increase in 3H-glucosamine incorporation into glycosaminoglycan.
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TNF not only stimulates production of specific growth factors, but
also stimulates production of specific growth factor binding sites.
Confluent fibroblasts stimulated with 50-500 ng of TNF for 24 hours
produced specific growth factors for colony formation by human bone
marrow granulocytes-macrophages (CFU-GM), erythroid (BFU-E), and
multipotential progenitor cells (CFU-GEMM) (289).

Furthermore, TNF

stimulated the production of epidermal growth factor (EGF) binding sites.
Palombella, et al. (193) reported a 67% increase in 1 25 I-EGF binding by
human diploid fibroblasts after 24 hour incubation with 1 ng/ml TNF
(193).

TNF treatment increased both the synthesis and maturation of EGF

receptor, thereby eliciting a 76% increase in the number of specific EGF
binding sites from 25,000 to 40,000 sites/cell (193).
Fibroblasts treated with TNF also are protected from the
pathological effects of encephalomyocarditis virus (EMC).

Kohase,

(130) reported that pretreatment for 24 hours with TNF at doses greater
than or equal to 3 ng/ml completely protected FS-4 fibroblasts from the
pathological effects of EMC virus.

This protective effect, as determined

by Kohase, resulted from IFN-P2 production by TNF stimulated fibroblasts.
However, closer examination by Reis, et al. (209) determined that the
protective effect resulted from IFN-P rather than IFN-P2 production by
TNF treated fibroblasts.
Lastly, TNF has an imrnunomodulatory effect on fibroblasts.
Collins, et al. (53) demonstrated that human dermal fibroblasts treated
with TNF had an enhanced expression of class I major histocompatibility
(MHC) antigens.

Class I MHC antigen expression increased approximately 9

fold after treatment with 20 U/ml of TNF for 4 days as a result of
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increased mRNA synthesis.

An additional immunoregulatory effect includes

the inability of TNF treated fibroblasts to perform an accessory role in
the production of IFN-7 by PH.A stimulated T cells.

Le and Vilcek (141)

demonstrated that FS-4 cells pretreated with 1-100 ng/ml TNF for 24 hours
failed to perform their accessory role in IFN-7 production by PH.A
stimulated T cells due, perhaps, to the release of a T cell inhibitor by
the TNF-activated fibroblasts.
4.

Endothelial cells
One of the functions of TNF is to enhance endothelial cell

adhesiveness, thereby increasing the propensity for PMN adherence to
endothelial cell surfaces.
exam~ned

Gamble, et al. (87) and Pohlman, et al. (205)

the stimulatory influence of TNF on endothelial cell ad-

hesiveness.

Incubation with 100 U/ml TNF for as little as 5 minutes

increased PMN adherence to the endothelial cell surface (87).

A maximal

25% increase in PMN adherence was achieved after endothelial cells were
incubated for 4 hours with 100 U/ml of TNF.

TNF enhanced adherence of

PMNs to endothelial cells may be by a protein synthesis dependent process
(87,205).

Pohlman, et al. (205) determined that TNF treatment induced

the expression of an endothelial cell surface factor which augmented
neutrophil attraction.

The function of the TNF induced endothelial cell

surface factor was to interact with the neutrophil membrane antigen
complex CDW18, thereby increasing the endothelial cell surface adherence
for PMNs.

This hypothesis prevailed after the observation that PMN

adherence to TNF treated endothelial cells decreased 65% after treatment
with the monoclonal antibody specfic for the membrane antigen complex
CDW18.

A similar mechanism is involved in the TNF enhanced leukocyte

23
adherence to endothelial cell surfaces observed by Pober, et al.
( 203,204).

Endothelial cells incubated with 200 U/ml of TNF for 4.5

hours demonstrated a significant increase in antibody H4/18 binding,
indicative of the expression of an endothelial cell surface protein which
is involved in endothelial cell-leukocyte adherence (203,204).
TNF also increases endothelial cell surface adhesiveness for T and
B lymphocytes.

Cavender,

~.

(43) observed a significant increase in

T and B lymphocyte binding to endothelial cells treated with 10 U/ml TNF
for 4 hours (43).

Experiments with specific monoclonal antibodies

suggested that TNF induced endothelial cell-lymphocyte binding is
mediated by an endothelial ceil surface receptor (43).

Pober, et al.

(204) established that TNF treatment induced a rapid elevation of the
endothelial cell intercellular adhesion molecule, ICAM-1.

ICAM-1

expression increased progressively during 24 hour treatment with 100 U/ml
TNF and may be the mechanism involved in T lymphocyte binding to
endothelial cells (204).
TNF not only influences the adhesiveness of the endothelial cell
surface for PMNs and lymphocytes, but TNF also modulates the growth of
endothelial cells both in vivo and in vitro.

In vivo, TNF had a

significant angiogenic effect; doses of 0.5 to 10 µg of TNF induced a
significant increase in the vascularization of the rabbit cornea (86).

In

vitro, however, TNF had a growth inhibitory effect.

Endothelial cells

inct·'-;.ted with 1 ng/ml TNF for 7 days had a 50% inhibition in cell
proliferation (86).

Normal cell growth resumed after TNFs' removal from

the incubation medium (86).

Stolpen, et al. (242) evaluated the

morphological changes that accompanied the growth inhibitory effect of
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TNF observed in vitro.

Human umbilical vein endothelial cells treated

with 20 to 100 U/ml of TNF for 72 to 96 hours became very elongated and
plump.

The cells were arranged in whorls and the uniform cell-cell

contacta were disrupted, which resulted in areas of overlapping cells.
Cytoskeletal changes included parallel arrays of actin filaments rather
than dense parallel bands and proteolytic degradation of fibronectin.
TNF is a potent inducer of blood procoagulant activity.
Bevilacqua, et al. (29) and Nawroth and Stern (186) evaluated the
procoagulant activity induced with TNF treatment of cultured endothelial
cells.

An increase in endothelial cell procoagulant activity was

demonstrated as early as 15 minutes after incubation with 100 U/ml TNF,
with a 4 to 15 fold rise evident ufter 4 hours (29).

This effect was

blocked by treatment with cycloheximide or actinomycin D, which suggested
that it was a protein synthesis dependent process (29).

Nawroth and

Stern attributed the procoagulant activity observed after TNF treatment
of endothelial cells to:

1) induction of tissue factor expression on the

endothelial cell surface; and 2) depressed thrombomodulin-dependent
protein C activated anticoagulant activity.
Growth factor production by endothelial cells is stimulated with
TNF.

Endothelial cells incubated with 100 U/ml of TNF for 8-24 hours

produced the hematopoietic growth factor, granulocyte-macrophage colonystimulating factor, GM-CSF (32,33).
stimulated GM-CSF

IIL~"\

production.

This effect resulted from TNF
Endothelial cells cultured with TNF

were demonstrated by Hajjar, et al. (98) to produce a smooth muscle cell
mitogenic factor.

Conditioned medium from endothelial cells cultured for

18 hours with 10 ng/ml of TNF induced a 90% increase in smooth muscle
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cell proliferation, whereas TNF alone stimulated only a 17% increase in
smooth muscle cell mitogensis.

Antibodies to platlet-derived growth

factor completely abolished the mitogenic activity, suggesting that TNFstimulated endothelial cells produced a platlet-derived growth factorlike molecule that was responsible for the smooth muscle cell proliferation.
Endothelial cell surface MHC class I antigen expression is
induced by TNF.

Collins, et al. (53) and Wedgewo0d, et al. (278)

demonstrated that TNF increased endothelial cell surface MHC class I
antigen but not class II antigen expression.

Incubation with TNF for 96

hours enhanced Hl.A-A,B antigens and P2-microglobulin expression 2 to 9
fold by increasing 100 fold the steady state level of the 1500 base pair
transcript for class I MHC heavy chains (53,278).

This was a protein

synthesis dependent process, for incubation with cycloheximide prevented
the increase in MHC class I antigen expression (53).

Leeuwenberg, et al.

(143) postulated that TNF increased endothelial cell MHC class I antigen
expression by stimulating IFN-P1 production.

They demonstrated, with

antibodies directed against IFN-P1. that IFN-P1 was important in
stimulating MHC class I expression by endothelial cells.

However,

Lapierre, et al. (139) determined that TNF induced MHC class I antigen
expression most likely was not mediated through the production of either
IFN-p, IFN-a, or IFN-P2Prostacyclin synthesis by va .. ~lar endothelial cells is increased
by treatment with TNF, as reported by Kawakami, et al.

(120).

Endo-

thelial cells incubated with 3.4 x 10- 9 M TNF for 24 hours produced more
than twice the amount of prostacyclin than did unstimulated cells.

The
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maximal prostacyclin secretory rate was o~served between 3 and 12 hours
8
after Stl.·mulation with 3.4 x lo- M TNF.
Lastly, TNF stimulates endothelial cells to synthesize and release
IL-1.

Maximal IL-1 activity is

produ~sd

by confluent endothelial cells

after incubation with 200 pM TNF for 20 hours (185).

TNF acted directly

on the endothelial cells to stimulate the production and release of IL-1,
since the addition of cycloheximide to the incubation medium prevented
the response.
5.

T and B lymphocytes
TNF has important immunomodulatory effects on both T and B

lymphocytes.

TNF does not effect resting T lymphocytes (225) but does

influence T cells activated with agents such as PHA or specific T cell
monoclonal antibodies (97,208,225,285).

Scheurich, et al. (225)

demonstrated that activated T cells incubated with 100 ng/ml of TNF for
48 hours had an increase Of 136% in HI.A-DR expression.

A 50% increase in

IL-2 receptors on OKT3 activated T cells was observed after 24 hour
incubation with 10 ng/ml TNF, thereby enhancing the sensitivity to IL-2
(225).
TNF also enhances the proliferation of activated T cells (97,208,
225,285).

Yokota, et al. (285) and Hackett, et al. (97) reported a 100-

600% increase in 3H-thymidine incorporation by activated T cells
stimulated with TNF for 72-96 hours.

TNF increased the number of mitogen

activated T cells entering the cell cycle (97).

R'

~es,

et al. (208)

reported that the thymocyte proliferatory response to TNF was species
specific:

recombinant murine TNF, not recombinant human TNF, at

concentrations of 78 to 2500 U/ml stimulated murine thymocyte
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proliferation in response to PHA.

These TNF induced responses on

activated T cells are related to the significant increase in TNF receptor
number, from 300 to 5000 sites/cell, subsequent to T cell activation
(225).

Additio11ally, PHA activation of T cells

of TNF (208).

sti~ulated

the production

Moreover, the production of TNF by activated T cells is

enhanced by IL-1, IL-2, and IL-4, suggesting that TNF production by
activated thymocytes might be involved in the thymocyte proliferation
stimulated by IL-1, IL-2, and IL-4 (208).
TNF is also important in cytotoxic T lyni.phocyte development.
Ranges, et al. (207) reported that 102 U/ml of TNF restored cytotoxic T
lymphocyte (CTL) generation in mixed lymphocyte cultures suppressed by
transforming growth
TGF-~

factor~

(TGF-~).

Part of the suppressive effect of

on CTL generation was related to the complete inhibition of TNF

generation by mixed lymphocyte cultures incubated with 1 ng/ml
(207).

From the observations of Ranges,

TGF-~

(207) and Jongeneel, et

al. (118), TNF was important in CTL development but was not essential.
Not only does TNF significantly influence activated T cells, but TNF
also significantly influences activated B cells.

Similar to activated T

cells, activated B cells were responsive to TNF stimulation as a
consequence of the increased number of surface TNF receptors: activated B
cells have 6000 TNF receptor sites/cell, compared to quiescent cells
which lacked detectable TNF receptors (122).

TNF significantly enhanced

the B cell immune response to T cell dependent antigens.

Jelinek,

(114) demonstrated that TNF enhanced the generation of immunoglobulin
secreting B cells stimulated by Staphylococcus aureus in the presence of
IL-2.

Ghiara, et al. (89) reported a similar finding:

TNF enhanced the
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in v1vo B cell response to the T cell dependent antigen, sheep red blood
cells, but did not enhance the B cell response to the T cell independent
antigen, type III pneumo- coccal polysaccharide (89).
TNF also stimulates 3H-thymidine incorporation by activated B
cells.

In the presence of B cell activators, such as the polyclonal B

cell activator and

Staphylococcus aureus, TNF enhanced 3H-thymidine

incorporation by B cells 4 to 6 fold (114,122).

The incorporation of 3H-

thymidine by activated B cells was further augmented by co-treatment with
IL-2 plus TNF (114,122).

Janssen and Kabelitz (113) reported a similar

stimulatory effect of .L'NF on Epstein-Barr virus (EBV) stimulated B cells.
TNF induced the rapid proliferation and differentation of a macrophagefree B cell preparation stimulated with EBV.
D.

EFFECTS OF TUMOR NECROSIS FACTOR AT THE ORGAN AND TISSUE LEVEL
1.

Liver
The liver performs vital roles in protein, glucose, and lipid

metabolism.

This section will review the literature concerning the

effects of TNF on hepatic:

1) amino acid uptake and acute phase protein

synthesis; 2) glucose production; and 3) lipid production.
In vivo and in vitro effects of TNF on hepatic amino acid uptake
was assessed by Warren,

~.

(275) using male rats.

TNF at a dose of 1

mg/kg significantly increased hepatic a-amino [l-14c]isobutyric acid
(AIB) uptake in vivo:
within 4 hours.

the AIB distribution ratio was elevated 5 fold

However, TNF failed to directly enhance basal AIB uptake

in vitro by isolated hepatocytes incubated for 20 hours with TNF at doses
of 0.03 to 30 pM.

Under stimulatory conditions with 5 nM glucagon, 0.3
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pM TNF significantly enhanced glucagon-stimulated AIB uptake from 200%
above basal to greater than 300% above basal.
TNF has a direct stimulatory effect on hepatic acute phase protein
synthesis both in vivo and in vitro.

Six hours after an i.p. injection

of 10-104 ng TNF/mouse, Sipe ~. (236) observed a dose dependent
increase in serum amyloid A (SAA) concentration.

Serum amyloid A

concentrations increased from a basal value of 2 µg/ml to 80 and 130
ug/ml by 6 and 20 hours, respectively, after the administration of 104 ng
of TNF.

Mortensen, et al. (181) reported a significant increase in serum

amyloid P (SAP) concentrations 24 hours after an i.p. injection of TNF:
SAP concentrations increased 4 fold after an i.p. injection of 5 x 104 U
of TNF/mouse (approximately 1 µg).

When 7.5 µg of TNF was given to each

mouse, a measurable increase in 2 other acute phase proteins was observed
24 hours post-injection; serum C3 and fibrinogen (181).
centration was elevated

~o

Serum C3 con-

809 µg/ml compared to 747 µg/ml for saline

treated controls, and fibrinogen concentrations doubled 24 hours after
TNF injection.

A significant increase in a fifth acute phase protein, C-

reactive protein, was demonstrated 24 hours after the subcutaneous
injection of 100-175 µg/m2 of TNF to cancer patients (276).

C-reactive

protein concentrations more than doubled, increasing from a pre-injection
concentration of 4.4 to 11.6 mg/dl within 24 hours after TNF administration.
Moldawer, et al. (178) examined the effect of chronic TNF
administration on hepatic acute phase protein synthesis in vivo.

Total

liver protein synthesis was significantly elevated to 167 mg/day in mice
given daily injections of 0.02 nmoles of TNF for 5 days compared to 136
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mg/day produced by freely fed control mice.

Chronic TNF treatment

significantly increased SAP concentrations approximately 7 fold to 46
µg/ml compared to the SAP concentrations in the control mice.

On the

contrary, chronic TNF treatment significantly decreased serum albumin
concentration to 34 mg/ml compared to 44 mg/ml reported for freely fed
control animals.
The in vitro effect of TNF on hepatic acute phase protein
synthesis was examined using isolated hepatocytes and hepatoma cell
lines.

Mortensen, et al. (181) evaluated the direct in vitro effect of

TNF on hepatic SAP synthesis using isolated hepatocytes.

A three fold

increase in SAP synthesis was produced after 24 hour incubation with 102104 U/ml TNF.

Perlmutter, et al. (199), Darlington, et al. (59) and

Mackiewicz, et al. (151) evaluated the effects of TNF on acute phase
protein synthesis using human hepatoma cell lines.

TNF, incubated with

isolated cells for 18 to 48 hours, significantly enhanced the synthesis
of the following acute phase proteins; factor B (199), factor C3
(59,199), and ceruloplasmin (151).

Perlmutter (199) and Mackiewicz (151)

reported a direct inhibition of hepatic albumin synthesis with 100 and
250 ng/ml TNF, respectively, whereas Darlington (59) reported no change
in albumin synthesis after treatment with 20-10,000 U/ml TNF.

The TNF

induced changes in hepatic acute phase protein synthesis reflected the
changes in respective mRNA synthesis induced by TNF (199).
The effects of TNF on hepatic glucose metabolism has not been
studied as extensively as the effects of TNF on acute phase protein
synthesis.

Rofe, et al. (212) examined the direct glucoregulatory

effects of TNF using isolated hepatocytes.

The glycogenolytic capacity
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of hepatocytes isolated from fed rats was unaltered by treatment with 1.2

nM

TNF for 60 minutes.

Furthermore, the gluconeogenic ability of

hepatocytes isolated from 24 hour fasted rats also was not effected by
TNF treatment:

incubation with 1.2 nM TNF treatment for 30 minutes did

not alter the gluconeogenic response to lactate, alanine, or glycerol.
Thirdly, the effect of TNF on hepatic lipid metabolism was tested.
Feingold, et al. (71) observed a stimulatory effect of TNF on
lipogenesis in vivo.

hepatic

Within 16-17 hours after the administration of

0.125 mg/kg TNF, rats demonstrated a significant increase in liver 3H20
incorporation into fatty acids (67 fold), cholesterol (2.9 fold), and
total non-saponifiable lipids (2.6 fold).

Liver slices obtained from

rats 16 hours after the administration of 0.125 mg/kg TNF demonstrated
similar effects in vitro:

acetate incorporation into fatty acids,

cholesterol, and total non-saponifiable lipids was increased 97%, 95%,
and 74%, respectively (71).

Closer examination revealed that TNF

enhanced lipogenesis by increasing HMG CoA reductase synthesis (71).

TNF

had no effect, however, on hepatic fatty acid utilization, triglyceride
synthesis, or ketone body production (212).
2.

Muscle
TNF significantly influenced 3 aspects of muscle physiology:

muscle fiber membrane potential; glucose metabolism; and protein
metabolism.
and in vitro.

TNF triggered muscle membrane depolarization both in vivo
T:

~ey,

et al., demonstrated the muscle membrane

depolarization activity of TNF both in rats (251) and in dogs (253).
Intravenous infusion of 0.6 and 1.8 mg/kg TNF produced a measurable
depolarization of hindlimb adductor muscle fibers 1 hour later; membrane
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potentials decreased from pre-injection values of -95.0 and -93.4 mV to
-85.S and -75.6 mV potentials 1 hour after infusions of 0.6 and 1.8 mg/kg
TNF, respectively (251).

Infusion of TNF directly into the hindlimb

muscle demonstrated significant depolarization within 5-10 minutes, the
magnitude and duration of which were dose dependent (253).

In vitro

studies conducted by Tracey, et al. (251,252) using rat extensor
digitorum longus and soleus muscles supported the hypothesis that TNF
acted directly on the muscle fibers in vivo to elicit an observable
membrane depolarization.

In agreement with the in vivo studies that

infused TNF directly into the hindlimb muscle, TNF dose dependently
induced significant muscle fiber membrane depolarization in vitro within
5 minutes.

nM TNF:

The largest change in membrane

pot~~tial

was observed with 10

membrane potential decreased from a pre-injection value of -71.6

mV to -58.6 mV after TNF treatment.
A second area influenced by TNF treatment is muscle glucose
metabolism.

A significant increase in glucose transport by L6 myotubes

was observed after 19 hours of incubation with 0.1-10 µg/ml TNF (142).

A

100% increase in 3H-2-deoxy-D-glucose uptake over control value~ was
demonstrated by myotubes incubated with 10 µg/ml TNF.

Concomitant with

the rise in glucose uptake was a significant increase in lactate production by the TNF treated muscles.

On the contrary,

Rafe, et al. (212)

observed no significant increase in lactate production by rat hemidiaphragms treated with 1.2 nM

Tc·~

for 2 hours.

However, Rafe did

demonstrate a 31% increase in glucose oxidation by the TNF treated rat
hemidiaphragms.
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A less defined, third effect of TNF on muscle physiology concerns
muscle protein metabolism.

Kettelhut,

~.

(126) reported no signi-

ficant effects on in vitro muscle protein degradation or synthesis using
soleus and extensor
treated rats.

digitoru.~

longus muscles isolated from TNF pre-

Regardless of the route of administration, intravenous or

subcutaneous, pretreatment with 4 mg/kg TNF in vivo did not influence
muscle metabolism in vitro 24 hours later.

Daily administration of TNF

for 5 days also failed to cause any measurable difference in muscle
protein metabolism in vitro by muscles isolated 6 hours after the fifth
injection (126).

Furthermore, TNF at doses of 104 to 105 U/ml incubated

directly with soleus and extensor digitorum longus muscles for 2 hours in
vitro also failed to significantly influence muscle protein metabolism
(126).

A comparable study performed by Rofe, et al. (212) measuring

alanine release as an index of rat hemidiaphragm protein degradation,
further supports the findings that TNF does not directly influence muscle
protein metabolism.
Contrary findings concerning muscle protein metabolism were
reported by Warren, et al. (276).

Cancer patients given an i.v.

injection of 10-100 µg/m2 TNF demonstrated a significant net efflux of
amino acids from the forearm by 6 hours:
doubled.

total amino acid efflux nearly

More specifically, net alanine and glutamine efflux increased

from control values of 105 and 144 nmoles/min/lOOml to 278 and 214
nmoles/min/lOOml, respectively, 6 hours after
3.

TN~

injection.

Adipose tissue and adipocytes
As discussed earlier in this dissertation, TNF mediates the

hypertriglyceridemia observed during chronic infection.

Chronic
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administration of exogenous TNF in vivo induced the same response.
Cancer patients administered TNF twice weekly for 4 weeks developed
significant hypertriglyceridemia (31).

Plasma triglyceride con-

centrations increased significantly from a
125 mg/dl after 4 weeks of treatment.

pretreat~ent

value of 119 to

However, the hyperlipemic effects

of TNF were also demonstrated much earlier (195).

As early as 3.5 hours

after an i.v. injection of 250 µg/kg TNF, rats developed a significant
hypertriglyceridemia, with triglyceride concentrations elevated to 210
mg/dl from a pre-injection value of 67 mg/dl (195).

This was not a

transient response since triglyceride concentrations remained elevated
for 7 hours (195).
There are several mechanisms responsible for the hyperlipemic
effect of TNF.
of TNF.

One mechanism is the lipoprotein lipase inhibiting effect

Semb, et al. (228) evaluated the effects of TNF on lipoprotein

lipase (LPL) activity using mice, rats, and guinea pigs.

TNF at doses of

10, 20, and 30 µg significantly depressed adipose tissue LPL activity in
mice, rats, and guinea pigs at 4, 6, and 15 hours post-injection,
respectively.

However, TNF significantly increased liver and plasma LPL

activity in all 3 animal models (228).

The hypothesis that TNF directly

suppressed adipose tissue LPL activity in vivo is supported by the in
vitro studies of Patton, et al. (196).

Using the murine adipocyte cell

line, 3T3-Ll, a dose dependent inhibition of heparin-releasable LPL
activity was exhibited after incubation with 0.01-100 nM TNF fo_ 16
hours.

Approximately 90% inhibition was demonstrated with 1 nM TNF.
Secondly, TNF induces hyperlipemia through the inhibition of lipid

synthesis.

Using 3T3-Ll cells, the influence of 0.0001-lOnM TNF on 3H-
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acetate uptake was investigated (196).
in a dose dependent manner:

TNF inhibited 3H-acetate uptake

80% inhibition of 3H-acetate uptake was

induced by treatment with 1 nM TNF for 24 hours.

TNF inhibited 3H-

acetate incorporation into ali classes of lipids, but especially

~h~

triglycerides.
Direct inhibition of key lipogenic enzymes is the mechanism
responsible f0c TNF-induced inhibition of lipid synthesis.

Pape, et al.

(194) determined that TNF directly inhibited the synthesis of an
important lipogenic enzyme using the pre-adipocyte cell line, 30A-5.
Incubation with 200 U/ml TNF for 8 days directly inhibited acetyl-CoA
carboxylase mRNA accumulation by 80% (194).

Treatment with TNF also

prevented pre-adipocyte differentiation and cellular lipid accumulation
as a result of inhibiting lipogenic enzyme synthesis (194,248).

Failure

to maintain lipid synthesis was observed after incubating mature adipocytes with TNF (248).

After 6 days of culture with macrophage con-

ditioned medium containing TNF, only 10% of the mature adipocytes had
identifiable lipid droplets; the rest of the cells had lost their stored
triglycerides.

The resultant loss in lipid droplets was caused by a

rapid decrease in the synthesis of key lipogenic enzymes:

within 12 to

24 hours after TNF addition, there was a 90% drop in lipogenic enzyme
mRNA levels (248).
Thirdly, TNF directly stimulates lipolysis, thereby increasing
serum triglyceride levels.

Using 3T3-Ll adipocytes, Patton, et al. (196)

demonstrated the lipolytic effect of TNF in vitro.

TNF at a dose of 1.5

nM directly increased free fatty acid efflux from 3T3-Ll adipocytes

Within 8 to 24 hours.

TNF, however, failed to influence fatty acid
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efflux from epidydimal fat pads removed from rats pre-treated with 4
mg/kg TNF for 4 hours (126).

Furthermore, both epidydimal fat pads (126)

and adipocytes {212) isolated from control rats failed to demonstrate a
direct effect of TNF on in vitro lipolysis.

Neither epidydimal fat pads

nor isolated adipocytes demonstrated an increase in glycerol release as a
result of incubation with 4 µg/ml or 1.2 nM TNF, respectively (126,212).
4.

Organ pathology
Close examination of major organs after in vivo treatment with TNF

revealed significant pathophysiological changes.
tract was very sensitive to TNF treatment.

The gastro-intestinal

For instance, Patton (195)

observed a 2.5 to 4.5 fold increase in the stomach weights of mice and
rats 3.5 hours after the i.v. injection of 0.25 mg/kg TNF.

Incomplete

gastric emptying, accompanied by swelling and gas retention, was
responsible for the increase in stomach weights.

Areas of infarction on

the cecum were rapidly observed even after sub-lethal doses of TNF
(195,249).

The small intestines exhibited areas of segmental ischemia,

inflammation, and edema after TNF treatment (195,210,249).

Microscopic

examination demonstrated mononuclear cell and neutrophil accummulation in
the lamina propria of villi and intestinal glands {195).

Electron

microscopic examination demonstrated necrosis of intestinal epithelial
cells with significant vacuolization of the cytoplasm (210).

The blood

vessels were lined by damaged endothelial cells, thus accounting for the
increased adherence of mononuclear cells and neutrophils to the endothelial cell surface (195), edema formation, and the accumulation of PMNs
and RBCs in the interstitium (210).

In some animals, TNF administration

resulted in intussusception of the ileocecal valve into the cecum (210).
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Assessment of TNF-induced liver damage revealed a significant
increase in liver weight compared to controls (88).

Histological

examination of TNF treated livers demonstrated hepatocyte swelling,
narrowing of liver canaliculi, and increased Kupffer cell number (88).
After chronic administration of TNF for up to _10 days, Tracey, et al.
(254) reported areas of focal parenchymal cell necrosis, extramedullary
hematopoiesis, and proliferation of small bile ducts in the portal
tracts.
Discrete areas of hemorrhage and scattered hyperemia were observed
in the lungs after TNF treatment (249,253).

Histological examination of

these areas revealed large arteries occluded by thrombi composed primarily of PMNs (249).

In rats, significant pulmonary edema occurred, as

reflected in the significant increase in lung wet weights from 696 to 941
mg after TNF treatment (88).

Tracey (253) reported significant

thickening of the alveolar membranes with peribronchiolar pneumonitis and
PMN infiltration.
Chronic exposure to TNF resulted in inflammatory cell infiltration
into the subendocardium of the heart (254).

This was associated with

significant hypertrophy and hyperplasia of intimal endothelial cells and
subintimal fibroblasts.

Focal areas of myocardial cell hypereosinophilia

and necrosis were also reported (254).
Changes also were observed in the kidneys, pancreas, and adrenal
glands as a result of TNF administration.

Kidneys became enlarged and

hyperemic, with discrete areas of tubular necrosis and damage to the
nephrons (249,253).

Focal areas of hemorrhage and inflammation were

present in the pancreas (249).

Medullary hemorrhagic necrosis as well as
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prominent inflammatory changes were observed in the adrenal glands after
TNF treatment (249,253).
5.

Alterations in body weight
Since TNF is responsible for mediating the severe cachexia

associated with chronic infection, then repeated administration of TNF
should result in severe weight loss.

Oliff, et al. (191) used an

interesting technique to replicate the chronic release of TNF in vivo
without administering repeated injections of TNF.

Oliff constructed a

rodent tumor cell line, CHO/TNF-20, which continuously secreted TNF and
inoculated nude mice with the TNF-secreting tumor cells.

During the

first 14 days, they reported an initial weight gain, after which the mice
began to lose weight.

By 32 days post-inoculation with the TNF secreting

tumor cells, animals had lost an average of 3.4g, or 17.6% of total body
weight.

Moreover, the TNF treated animals lost all body fat:

autopsy

revealed no prominent iutrascapular, perirenal, or subcutaneous fat.

The

severe wasting associated with the TNF secreting tumor was associated
with a significant drop in food intake.
The suppressed food consumption associated with TNF secretion from
the TNF-secreting tumors was substantiated in young and adult rats given
repeated injections of TNF (126,254).

Within 24 hours after the first

TNF injection, a 33% and 60% drop in food consumption were reported for
young and adult rats, respectively (126,254).

Even though repeated TNF

administratior {,nduced a 20-30% decrease in food intake, the rate of
growth relative to food consumption was similar for both the control and
TNF treated rats (126).

The weight loss observed in the TNF treated rats

was similar to the weight loss observed in the pair-fed controls (254).
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There was a

signifi~ant

difference, however, in protein and fat content

between the pair-fed controls and the TNF treated rats.

Pair-fed control

animals demonstrated a drop i.n percent body fat from 11.9% to 6.0% and no
change in protein content.

TNF treatment, however, resulted in little

fat mobilization, observed as a slight drop in percent body fat from
11.9% to 8.3%, and a significant .mobilization of protein, reflected by a
decrease in percent protein from 22.7 to 19.8%.

Therefore, TNF induced

cachexia resulted from suppressed food intake and altered fuel mobilization.
E.

FEVER INDUCING PROPERTIES OF TUMOR NECROSIS FACTOR
TNF has thermoregulatory effects in rabbits, rats, mice, and humans.

Dinarello, et al. (66) were first to demonstrate the dose-dependent
fever-inducing properties of TNF.

Using rabbits, a monophasic fever

response was elicited after an i.v. injection of 1 µg/kg TNF:

peak

temperature elevation occurred within 48-54 minutes post-injection and
returned back to basal levels by 180 minutes.

When the dose of TNF

administered was increased 10 fold to 10 µg/kg, a biphasic fever profile
was demonstrated (66):

The initial peak in temperature, which cor-

responded to the monophasic peak observed after the 1 µg/kg dose of TNF,
was followed by a second peak at 3.5 hours post-injection.

Pre-

treatment with ibuprofen (10 mg/kg) blocked the initial rise in
temperature, indicating that it resulted from TNF-induced prostaglandin
release.

The second fever pe .. · , however, was due to TNF- induced IL-1

release (66).
Thermoregulatory changes induced by TNF administration were
dependent not only on the dose but also on the route of administration.

r
40
young rats (60g) given an i.v. injection of 4 mg/kg TNF had a measurable
drop in rectal temperature

fro~

36.8 to 34.3°C by 1 hour (125).

Just

prior to death, i.e. 3-4 hours after injection, rectal temperature had
dropped further to 29.5-32°C.

However, i.p. or subcutaneous injections

of 4 mg/kg TNF resulted in the opposite response (126).

A significant

hyperthermia was measured in these rats 3 and 4 hours after i.p. and
subcutaneous injections, respectively.

Three hours after the peak

hyperthermic response, temperatures began to fall and returned to control
levels within 24 hours.
Contaminating endotoxin in the recombinant TNF preparation was not
responsible for the thermoregulatory activity of TNF.

Mannel evaluated

the thermoregulatory activity of TNF using both ETX-sensitive (C3H/HeN)
and ETX-resistant mice (C3H/HeJ) (154,156).

Within 5 hours after i.v.

injections of 3-4 mg/kg TNF to C3H/HeN and C3H/HeJ there was a significant decrease in body temperatures from 38 to 30°C in both groups of
mice.

If the hypothermic effect of TNF had resulted from contaminating

ETX in the TNF preparation, then the ETX-resistant mice would have failed
to demonstrate a significant thermoregulatory effect.
Finally, there is substantial evidence which demonstrated significant febrile responses shortly after TNF administration to humans.
Blick, et al. (31) and Warren, et al. (276) examined the in vivo effects
of TNF administered to cancer patients as an anti-neoplastic drug twice
weekly for 4 weeks.

Regardless of the route

r

administration, intra-

venous, intramuscular, or subcutaneous, a significant febrile response
was determined.

The time to peak temperature elevation, however, varied

according to the route of administration:

patients that received 10-100
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µg/m2 TNF i.v. demonstrated peak elevation in body temperature within 1-2
hours whereas 4-8 hours were required after the subcutaneous injection of
l00-175 µg/m2 TNF (276).

Associated with the febrile response were

numerous clinical flu-like symptoms such as headache, fatigue, chills,
and rigor (31,276).
F.

HEMODYNAMIC CHANGES INDUCED BY TUMOR NECROSIS FACTOR
The hemodynamic effects of TNF were examined using beagle dogs

(253), rats (13), and cancer patients (31,276).

Anesthetized beagle

dogs, infused intra-arterially with a non-lethal dose of 10 µg/kg TNF,
hdd a measurable drop in mean arterial blood pressure (MBP) from a preinjection control value of 145 mmHg to 113 mmHg 1 hour post-infusion
(253).

In spite of the fall in MBP, there was no measurable change in

heart rate.

When a non-lethal dose of TNF was infused into conscious

rats, a slightly different hemodynamic profile was observed.
~-

(13) reported no measurable

ch~nges

Bagby, et

in MBP and heart rate either

during the infusion of 0.15 mg/kg TNF over a period of 3 hours or for 2
hours after completion of the infusion.

Similar findings were reported

in the clinical trials conducted by Blick, et al. (31) and Warren, et al.
(276):

conscious cancer patients administered non-lethal doses of TNF

demonstrated no measurable change in mean arterial pressure.
More dramatic hemodynamic changes were observed after highly lethal
doses of TNF were administered to beagle dogs (253) and rats (249).
Anesthetized beagle dogs infused over 40 minutes with 100 µg/' ...., TNF
demonstrated a rapid drop in mean arterial pressure from 141 to 45 mmHg
by 3 hours after completion of the infusion (253).

Heart rate, however,

was unaltered and remained at an average rate of 166 beats per minute
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•te of the significant hypotensive response.
inspi

Similarly, anesthetized

Sprague-Dawley rats infused with a highly lethal dose of 1.8 mg/kg TNF
demonstrated a significant 40 mmHg drop in systolic pressure approximately 75 minutes after onset of the infusion (249).

This was a

transient hypotensive response, for systolic pressure returned to near
control values by 120 minutes.
anesthetiz~<l

Unlike the anesthetized beagle dogs,

rats demonstrated a significant elevation in heart rate from

450 to 550 beats per minute within the first 60 minutes after onset of
TNF infusion.
G.

METABOLIC GRANGES INDUCED BY TUMOR NECROSIS FACTOR
1.

Plasma glucose
Non-lethal doses of TNF have no effect on plasma glucose con-

centrations in both human cancer patients and experimental rats.

Plasma

glucose concentrations remained at control values for as long as 6 hours
after the subcutaneous injection of 100-175 µg/m2 TNF to human cancer
patients (276).

Although there was no net change in plasma glucose

concentrations for conscious rats infused with a sub-lethal dose of TNF
(13), there were measurable changes in the rates of glucose appearance
and utilization.

Bagby, et al. (13) demonstrated a 25% increase in the

rate of plasma glucose appearance during the 3 hour infusion of 0.15
mg/kg TNF.

Concomitant with the increased rate of glucose appearance was

a 28% increase in glucose utilization (173).

Meszaros, et al. (173)

determined that the macrophage-rich tissues, such as spleen, liver, and
kidneys, were largely responsible for the increased glucose utilization
measured after TNF administration (173).

Hence, even though there were
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no measurable changes in plasma glucose concentrations, TNF did increase
both glucose production and glucose utilization.
Significant changes in plasma glucose concentrations were demonstrated after lethal doses of TNF.

A significant hyperglycemic effect

of TNF was determined in 60 g rats as well as adult rats.

Kettelhut,

al. (125), using 60 g rats, evaluated the glucoregulatory effects of TNF
by changes in venous plasma glucose concentrations from samples taken by
jugular vein puncture.

TNF significantly increased venous glucose

concentrations from 130 mg/dl to 200 mg/dl within 1 hour after the i.v.
administration of 4 mg/kg TNF.

Tracey, et al. (249), using anesthetized

adult rats infused with 0.2-1.8 mg/kg TNF, reported elevated plasma
glucose concentrations betweem 15 and 90 minutes after TNF administration.

At the later time points after lethal injections of TNF,

significant hypoglycemia was observed.

Two hours after TNF injection,

Kettelhut (125), using 60 g rats, reported a significant drop in venous
plasma glucose concentrations to approximately 30 mg/dl.

Bauss, et al.

(16) reported a similar hypoglycemic response in C3H/HeN mice 6 hours
after injection with 3.0 mg/kg TNF.

Plasma glucose concentrations,

determined for samples taken under ether anesthesia, dropped to
approximately 60 % of control values.
2.

Plasma lactate
Dose dependent changes in plasma lactate were observed after TNF

administration.

Non-lethal doses of TNF induced no significant changes

in plasma lactate concentrations for as long as 3-5 hours after administration to adult rats (13) or anesthetized beagle dogs (253).
contrast, significant hyperlactacidemia was observed after the ad-

In
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winistration of lethal doses of TNF.

Tracey, et al. (253) reported a 4

fold increase in plasma lactate 3 hours after the infusion of a lethal
dose of TNF, 100 µgjkg, to anesthetized beagle dogs:

plasma lactate

concentrations increased from 0.66 to 2.55 mM by 3 hours.

When Tracey,

sa.t al. (249) examined the hyperlactacidemia-inducing property of TNF in
anesthetized rats, a similar response was observed.

Anesthetized rats

given a lethal infusion of 1.8 mg/kg TNF demonstrated a 3 to 5 fold
increase in plasma lactate concentrations compared to pre-infusion
values.

A smaller increase was reported for mice injected with a lethal

dose of TNF:

only a 160% increase in plasma lactate concentrations was

determined for samples taken under ether anesthesia within 6 hours after
the injection of 3.0 mg/kg TNF (16).
H.

NEURO-ENDOCRINE CHANGES INDUCED BY TUMOR NECROSIS FACTOR
1.

Insulin and glucagon
The effects induced by TNF on the pancreatic hormones, insulin and

glucagon, were examined in vivo as well as in vitro.

The in vivo changes

in plasma insulin and glucagon concentrations induced by TNF were dose
dependent and model dependent.

When tested in cancer patients, non-

lethal doses of TNF (100-175 µg/m2) injected subcutaneously elicited no
significant changes in either plasma insulin or glucagon concentrations
(276).

Plasma insulin and glucagon concentrations were 65 µU/ml and 354

pg/ml, respectively, prior to injection and were not significantly
different 6 hours after TNF injection at 43 µU/ml and 429 pg/ml, respectively.

Significant changes in plasma insulin as well as glucagon

concentrations, however, were reported for studies performed in animal
models.

Bagby, et al. (13) demonstrated a transient 3 fold

in~rease

in
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plasma insulin concentrations within 1 hour after the onset of a nonlethal infusion of TNF in conscious rats.

Plasma insulin concentrations

were 30 and 9 µU/ml in TNF and saline treated rats, respectively.
Although the plasma insulin concentrations were 3 fold higher in the TNF
treated rats compared to the saline controls, the pre-injection insulin
concentrations were not determined for either group of rats.

Since the

real control value for the TNF treated rats is the pre-injection insulin
concentration, it is difficult to definitely conclude that TNF induced a
hyperinsulinemic response.
Significant dose dependent changes in plasma glucagon concentrations also were induced after TNF administration.
reported no significant

ch~nge

Tracey, et al. (253)

in plasma glucagon concentrations 3 hours

after the infusion of a non-lethal dose of TNF (10 µg/kg) in anesthetized
beagle dogs.

Although there was a slight elevation in plasma glucagon

concentration 3 hours after TNF infusion, the difference was not statistically significant, ie. 179 and 98 pg/ml, respectively.

However, a

significant rise in plasma glucagon concentration was induced after the
administration of a lethal dose of TNF (109 µg/kg) to anesthetized beagle
dogs (253).

Plasma glucagon concentrations increased from a control

value of 64 to 558 pg/ml within 3 hours after a lethal dose of TNF.
Similarly, a significant elevation in plasma glucagon concentration was
observed in conscious rats infused with a non-lethal dose of TNF.
et al. (13)

~eported

Bagby,

significantly elevated plasma glucagon concen-

trations for the TNF infused rats compared to the saline treated rats at
1 and 3 hours after start of the TNF infusion:

plasma glucagon con-

centrations were 530 and 607 pg/ml, respectively, for the TNF treated
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rats compared to 276 and 287 pg/ml, respectively, for the saline treated
rats.

The limitation of this study is that Bagby failed to report the

pre-infusion glucagon concentrations for both groups of rats, thereby
making it difficult to definitely conclude that TNF induced significant
hyperglucagonemia.
Direct in vitro effects of TNF on pancreatic hormone secretion
were examined using isolated pancreatic Islets of Langerhans.

TNF

reduced insulin release from isolated rat islets by 40% (18).

As

reported by Bendtzen, et al. (18), islets incubated with TNF at doses
greater than 1 µg/ml for 6 days exhibited a 40% reduction in insulin
release.

TNF suppressed insulin release without damaging islet integrity

(153) or changing insulin content (18).
Profound modulation of pancreatic hormone release was observed
after treatment with TNF in combination with IL-1 (152) and IFN-7 (206).
TNF, at doses as low as 25 ng/ml, potentiated 5 to 10 fold the inhibitory
effect of IL-1 on glucose-stimulated insulin release by cultured islets
(152).

Moreover, cultured islets pretreated with 2 ng/ml IL-1 prior to

incubation with 2.5 ng/ml TNF released 36% less insulin than islets pretreated with TNF prior to incubation with IL-1 (152).
the cytotoxic effects of IFN-7.

TNF also enhanced

Pukel, et al. (206) determined that rat

islet cell monolayers incubated for 4 days with 25 ng/ml TNF plus 1000
U/ml IFN-7 released more intracellular 5lcr than did cells incubated with
IFN-7 alone; 36.8% versus 7

~%,

respectively.

Even greater islet cell

cytotoxicity was demonstrated after treatment with all three mediators;
TNF, IL-1 and IFN-7.

Co-treatment with 1000 U/ml IFN-7 plus 25 ng/ml TNF
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plus 0.39 ng/ml IL-1 resulted in the release of 47% of intracellular

Slcr.
TNF mediates p cell destruction in vivo not only by enhancing the
cytotoxic activity of IFN-1 and IL-1, but also by increasing the expression of MHC class I antigens on

P cells

(37).

Campbell, et al. (37)

reported that incubation for 6 days with 20 ng/ml TNF increased the
expression of MHC class I proteins on human and mouse

P cells.

An

increase in class II MHC antigen expression was observed after cotreatment with IFN-1 (500 U/ml) plus TNF (10 ng/ml).
2.

Plasma catecholamines
Changes in plasma epinephrine and norepinephrine concentrations

induced by TNF administration were dose dependent.

Non-lethal doses of

TNF induced either no change (253) or an increase (13) in plasma
catecholamines.

Tracey, et al. (253) reported no significant changes in

plasma epinephrine or norepinephrine concentrations measured in anesthetized beagle dogs after infusion of a non-lethal dose of TNF (10
µg/kg).

Bagby,~.

(13), however, demonstrated a significant increase

in plasma epinephrine and norepinephrine concentrations after the infusion of a non-lethal dose of TNF (150 µg/kg) in conscious rats.

Plasma

epinephrine concentration was significantly elevated 1 hour after onset
of the TNF infusion relative to the concentration reported for the saline
treated rats; 447 vs. 170 pg/ml, respectively.
epinephrine and norepinephrine concentrati
relative to the saline treated rats:

·3

By 3 hours, both plasma
were significantly elevated

plasma epinephrine and nor-

epinephrine concentrations for the TNF treated rats, 583 and 460 pg/ml,
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respectively, were significantly greater than the corresponding values
determined for the saline treated rats, 167 and 182 pg/ml.
The influence of a highly lethal dose of TNF on plasma
catecholamine concentrations was examined by Tracey, et al. (253).
Anesthetized beagle dogs infused with 100 µg/kg TNF demonstrated significant elevations in plasma epinephrine and norepinephrine concentrations.

Plasma epinephrine increased from a pre-injection value of 58

pg/ml to 1148 pg/ml within 15 minutes after the infusion of TNF.

By 3

hours, plasma epinephrine was significantly elevated at 1623 pg/ml
relative to the baseline control.

Plasma norepinephrine concentrations

increased significantly from a baseline value of 282 pg/ml to 1400 and
1982 pg/ml by 15 and 180 minutes, respectively, after TNF infusion.
3.

Plasma cortisol
The influence of TNF on a stress and glucoregulatory hormone,

cortisol, also was evaluated.

Plasma cortisol concentrations are

elevated even by non-lethal doses of TNF.

As reported by Warren, et al.

(276), cancer patients injected subcutaneously with a non-lethal dose of
TNF, 100-175 µg/m2, had significantly elevated serum cortisol concentrations 6 hours after TNF administration:
from 18 to 30 µg/ml.

plasma cortisol increased

Tracey, et al. (253), however, reported a

significant increase in plasma cortisol only after a lethal infusion of
TNF in anesthetized beagle dogs.

Plasma cortisol increased greater than

3 fold, from 42 to 146 ng/ml, as early as 15 minutes after . lethal
infusion of TNF and remained elevated for as long as 3 hours after the
infusion.
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I.

MORTALITY AND MORBIDITY INDUCED WITH TUMOR NECROSIS FACTOR.
Lethal, shock-like effects were induced by TNF in mice, rats and

dogs.

Mice were the most resistant, compared to rats and dogs, to the

lethal effects of TNF.

The LD50 dose for TNF administered as an i.p.

bolus injection to adult mice was 300 µg/mouse (approximately 12 mg/kg)
for a 48 hour observation period (15).

Approximately 10% and 80%

mortality rates were observed after subcutaneous and i.p. injections of 8
and 20 mg/kg TNF, respectively, in adult mice (145,214).

However, when

injected intravenously, mice were more sensitive to the lethal effects of
TNF:

67% of ti1e mice died by 24 hours after an i.v. bolus injection of

4.3-4.5 mg/kg TNF (16).

Rats, on the other hand, were more sensitive

than mice to the lethal effects of TNF.

The LD50 dose, determined for a

12 hour observation period, was calculated to be 0.7 mg/kg for adult rats
given an i.v. bolus injection of TNF (249).
rates of 64% were observed after the i.v.

Although similar mortality

injec~ions

of 0.6 and 1.8 mg/kg

TNF, the mean survival time was less for the 1.8 mg/kg treated rats
(249).

One hundred percent of both young and adult rats died after the

i.v. injections of 4.0 and 3.6 mg/kg TNF, respectively (125,249).'

When

TNF was administered as an i.v. continuous infusion, no deaths were
observed after the 3 hour infusion of 0.15 mg/kg TNF (13).

More chronic

administration of TNF, as reflected in the 5 day infusion of 0.1 mg/kg
TNF/day, produced a mortality rate of 20% during the 5 day study (88).
When a comparable dose of TNF was infused into anesthetized beagle dogs,
ie. 0.1 mg/kg, all of the dogs died within 3 hours (253), indicating that
dogs were more sensitive than rats and mice to the lethal effects of TNF.
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Additionally, lethal as well as non-lethal doses of TNF induce
clinical signs commonly associated with infections in both animal models
and human cancer patients.

Clinical signs of morbidity, such as diar-

rhea, ruffled fur, piloerection, tachypnea, and ocular exudates were
observed after TNF administration to mice and rats (16,88,125,145,214,
249).

Similarly, clinical flu-like symptoms, such as headache, fatigue,

chills, nausea, and rigur, were reported by human cancer patients injected with non-lethal doses of TNF (31,175,276).

J.

RATIONALE
Information concerning tl.e role of TNF as a mediator of the patho-

physiological changes associated with septic shock has escalated since
the demonstration by Beutler,

~.

(26) that passive immunization

against TNF protected mice from the lethal effects of ETX.

Although

numerous studies have evaluated and compared the alterations induced by
TNF to those asaociated with endotoxicosis and sepsis (13,16,24,103,125,
126,142,145,156,161,173,174,175,249,250,251,253) a clear dose- and timerelated study evaluating the hemodynamic, metabolic, and neuro-endocrine
alterations induced by comparably lethal doses of TNF and ETX has not
been examined in conscious, unrestrained, cannulated, adult rats.

Ad-

ditionally, the interactions of these two agents to elicit a highly
lethal response has not been evaluated with relation to the hemodynamic,
metabolic, and endocrine alterations induced after co-treatment with low
doses of TNF and ETX.

Furthermore, the direct in vitro ability of TNF to

act as a glucoregulatory agent has not been examined using the isolated
perfused rat liver preparation.

Although Rofe, et al. (212) briefly

evaluated the direct effect of TNF on isolated hepatocytes, a dose-
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dependent study has not been performed.

Therefore, this study was

performed to address specific in vivo as well as in vitro effects of TNF.

CHAPTER III
MATERIALS AND METHODS

A.

ANIMALS
Male Holtzman rats weighing approximately 350-400 grams were used

for all experiments.

Rats were obtained from either the Holtzman Co.

(Madison, Wt) or Sasco-King (St. Louis, MO).

The rats were housed in

stainless steel wire mesh cages while maintained in a temperature of 24°C
for at least 5 days prior to experimentation on a 12 hour light (07001900)/dark cycle.

Purina rat chow and tap water were allowed ad libitum

throughout the acclimat5on period.

All experiments were initiated

between 1000 and 1400 hours.
B.

AGENTS
1.

Tumor necrosis factor
Recombinant human tumor necrosis factor-a (TNF) used for this

study was either donated by Genentech Inc. (courtesy of H. Michael
Shepard; South San Francisco, CA) or purchased from Amgen Biologicals
(Thousand Oaks, CA).

The Genentech TNF was lot #3056-55 with a specific

activity of 5.02 x 107 units/mg protein, as assessed by lysis of
actinomycin D treated L-M cells.

This supply of TNF was received as a

solution of 0.5 mg TNF/ml of buffer, containing monobasic and dibasic
sodium phosphate and sodium chloride, pH-7.0.
was determjned by

Genen~ech

Endotoxin contamination

to be less than or equal to 0.125 endotoxin

units/ml, which is equivalent to 0.25 endotoxin units/mg of TNF (Limulus
Amoebocyte Lysate Assay; 1 endotoxin
52

unit~

0.1 ng of ETX).

TNF
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purchased from Amgen Biologicals was lot #902 with a specific activity of
8

x 106

~nits/mg

L9 29 cells.

protein, as assessed by lysis of mitomycin treated mouse

Amgen Biologicals' TNF was received as a solution of 0.3 mg

TNF/rnl of 40 mM Tris/0.1 M NaCl, pH-8.5.

Contaminating endotoxin content

was assayed by Amgen and was found to be less than 2.5 endotoxin units/mg
protein (Limulus Amoebocyte Lysate Assay).
2.

Heat-inactivated tumor necrosis factor
For one set of in vivo experiments, heat-inactivated TNF (H.I.-

TN~)

was used as a control for the contaminating endotoxin inherent in a

recombinant TNF preparation.

Heating the TNF solution to 80°C for 60

minutes inactivates the monokine but not the small quantity of con-.
taminating endotoxin.

For this reason, changes induced in the H.I.-TNF

treated animals were probably the result of the contaminating endotoxin.
3.

Endotoxin
Lyophilized Salmonella enteritidis lipopolysaccharide Boivin, lot

#733346, was purchased from Difeo Laboratories (Detroit, MI).

For use in

these experiments, the lipopolysaccharide (endotoxin; ETX) was suspended
in 0.9% sodium chloride.
C.

IN VIVO EXPERIMENTS
1.

Cannulation procedure and feeding regimen
For one set of experiments, rats underwent surgery at 1400 hours

on the day prior to experimentation.

Rats were anesthetized with either

5% Halothane (Halocarbon Tqboratory Inc .. Hackensack, N.J.) in 100%
oxygen until the animal became unconscious, or an i.v. injection of
sodium pentobarbital (46 mg/kg).

A midline incision was made on the neck

and the area was blunt dissected to expose the left carotid artery and
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the right jugular vein.

Heparinized polyethylene tubing (PE-50) was

inserted into each vessel and advanced approximately 3 cm to either the
ascending aorta aorta for the arterial line or to the junction of the
right atrium and superior vena cava for the venous line.

Each cannula

was tied in place, was tunneled under the skin, and was exteriorized on
the back of the neck.

Animals were placed in individual cages with water

and observed for post-surgical complications.

These animals were not

provided with food after surgery and so are considered to be in a fasted
state for the experiment conducted at 1000 hours the next morning.
For the second set of experiments, cannulae were implanted on the
morning of experimentation.

Ad libitum fed animals were anesthetized

with Halothane and surgery was performed in the same manner as described
above.

The rats were given 4 hours to recover from surgery before the

experiment was begun.
free access

t~

Because the surgery was performed on rats that had

food, they are considered to be fed animals at the time of

experimentation.
2.

Experimental procedure for cannulated rats
Prior to the onset of experimentation, each cannula was extended

with an additional piece of PE-50 tubing.

The arterial line was con-

nected to a saline filled Statham pressure transducer (model number P23)
which was used to record pulsatile as well as mean blood pressure, to
determine pulse rate, and to obtain arterial blood samples.
the venous line provided a convenient mt

"1S

Extension of

for i. v. inj ec ti on of saline,

H.I.-TNF, TNF at 0.1, 0.5, or 1.0 mg/kg, ETX at 1.55 or 30 mg/kg, or cotreatment with TNF plus ETX at 0.1 and 1.55 mg/kg, respectively.

Before

SS
beginning each experiment, rats were acclimated to their environment as
determined by normal, steady blood pressures and quiet behavior.
Arterial blood samples were taken prior to and at 30, 60, 90,
l20, 180, or 360 minutes after i.v. injection, depending upon which plasma constituents were to be measured in each blood sample.

For experi-

ments in which plasma glucose, lactate, insulin, corticosterone, norepinephrine, and epinephrine concentrations were determined, arterial
blood samples (l.S ml) were taken prior to and at 30, 90, 180, and 360
minutes post-injection.

Experiments for which only plasma glucose,

lactate, and insulin concentrations were measured, samples (0.8 ml) were
taken prior to and at 30, 60, 90, and 120 minutes post-injection.

Re-

gardless of which sampling schedule was followed, plasma was removed trom
each blood sample and the red blood cells (RBCs) were resuspended in an
equal volume of saline and returned intravenously to each animal.

Blood

volume depletion and the complications associated with that condition
were minimized by handling the animals in this manner.
Upon completion of each experiment, the carotid artery and jugular
vein cannulae were resealed and rats were allowed free access to water.
For the next 24 hours, these animals were periodically checked to
determine survival.

Additionally, each animal was surgically checked

either at death or after 24 hours to insure that their cannulae were
placed in the appropriate location and for any gross organ pathology.
3.

Glucan treated animals
Under light ether anesthesia, rats were injected i.v. with saline

or 10 mg/kg particulate glucan (lot #lFSSOO; Fleischmann Laboratories;
Stamford, CT) suspended in saline.

Animals were returned to our animal
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research facility and allowed food and water ad libitum.

Seventy-two

hours later, these rats were anesthetized with ether and injected i.v.
with either saline, TNF (0.1 mg/kg), or
monitored to
D.

determin~

ETX (1.25 mg/kg) and were

24 hour survival.

ISOIATED.PERFUSED RAT LIVER EXPERIMENTS
1.

Liver perfusion apparatus
Livers were perfused in a liver Perfusion-Aeration Apparatus

(Medical Research Apparatus; Clearwater, FL).

Krebs bicarbonate buffer

(KRB; 118 mM NaCl, 4.7mM KC!, 2.5mM CaClz-2HzO, l.2mM KH2P04, l.2mM
MgS04-7HzO, and 25mM NaHC03) containing 2 mg/ml bovine albumin (RIA
gr~de;

Sigma ) was continuously recirculated through the system using a

Masterflex peristaltic pump (Cole-Parmer Instrument Co.; Chicago, IL).
Total volume of perfusion fluid continuously recirculated through the
system was 150 ml.

Temperature was maintained at 36-37°C with a heat

lamp and heating wires.

The perfusate was oxygenated continuously with

95% Oz / 5% COz by passing over a gas exchange lung.

Two lucite filters

lined with silk mesh were used to filter the perfusate free of any
particulate or fibrous material which the liver may have produced during
the perfusion.
Oxygen tension in the perfusion fluid going to and coming from the
liver was measured with a YSI model 53 biological oxygen monitor (Yellow
Springs Instrument Co., Inc.;

Y~llow

Springs, OH).

Glucose and lactate

concentrations in the perfusate as a result of net liver production were
measured continuously with YSI model 26 continuous glucose and lactate
monitors, respectively.

Both glucose concentration and oxygen saturation

in the perfusate were recorded continuously on a Linear 1202 chart
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recorder (Linear Instrument Corporation; Reno, NV).

A Gilmont spherical

float flowmeter (size number 3; Thomas Scientific; Swedesboro, NJ) was
used to determine flow rate to the liver.

Livers were perfused with an

average flow rate of 50 ml/min.
2.

Liver removal
Fed rats were injected i.v. with sodium pentobarbital until there

was only a slight

res~onse

to a tail pinch.

This insured that the

animals were anesthetized adequately without significantly depressing
liver blood flow.

A midline abdominal incision was made and followed by

2 lateral incisions, one to the right and left side.
access to the portal area.

This provided easy

The intestines were reflected gently to the

animal's left side, thus exposing the portal vein and abdominal vena
Heparin (500 units/rat) was injected into the abdominal vena cava

ca~a.

and was allowed to circulate in the animal for 5 minutes before proceeding with the rest of the surgery.

The portal vein was cannulated

with PE-260 tubing and flow to the liver established immediately with
KRB.

Quickly the chest was opened with a midline incision and outflow

from the liver was established by cannulating the thoracic vena cava
through the right atrium with PE-260 tubing.

Yith KRB rapidly flushing

the liver of all RBCs, the liver was excised gently from the animal and
was placed in the perfusion chamber within 4 minutes from the time the
portal vein was cannulated.
3.

Liver perfusion
The excised liver was placed on a glass platform, inflow

established, and outflow adjusted such that the liver was not distended
but was perfused well.

Temperature,

Oz

tension, glucose (mg/dl) and
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lactate (mg/dl) were measured in the perfusate coming from the liver
before it returned to the reservoir.

The perfusion fluid was mixed in

the reservoir prior to being pumped through a lucite filter to the gas
exchange lung.

After passing over the lung, the perfusate was filtered

through a second filter, and was pumped to the liver, constantly
measuring flow rate and oxygen tension.
standing level of perfusate in the

gla~s

The difference between the
lung and the level of inflow to

the liver was used to determine the pressure head, which averaged 20 cm
of H20 for these experiments.
Oxygen consumption rate by the liver was calculated from the
difference in 02 tension in the perfusate going to and coming from the
live~

using the formula: µl 02/min/gm liver - Oxygen amount in

solution(µl/ml) x flow rate(ml/min) x difference in 02 saturation(%)/100
x l/gm liver wet weight.

Net glucose production rate by the liver was

calculated in the following manner:

µmoles glucose/gm liver wet

weight/hour - [8mg glucose produced in 5 minutes/100 ml] x 150ml x 1000
µmoles/180 mg x 12/hour x l/gm liver wet weight.
production rate was

~alculated

as follows:

Net liver lactate

µmoles lactate/gm liver wet

weight/hour - [8mg lactate produced in 5 minutes/100 ml] x 150 ml x 1000
µmoles/90 mg x 12/hour x l/gm liver wet weight.
The initial 30 minutes of perfusion were used as a control period.
During this time, net glucose production and oxygen consumption reached a
steady state.
~rder

Perfused livers had to meet the following criteria in

to be included in this study:

production rate

= 94

1) average basal net glucose

µmoles glucose/gm liver wet weight/hour; 2) average

basal oxygen consumption rate

= 57

µl of oxygen/gm liver wet weight/
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minute; 3) average flow to the liver

~

50 ml/minute; 4) good liver color;

and 5) well perfused liver lacking areas of inadequate perfusion or
swelling.

If any of these criteria were compromised, the liver perfusion

was terminated and data not included in the study.
After the control period, either 1 ml of phosphate buffered saline
(PBS) or 150 or 300 µg of TNF was added directly to the perfusion
reservoir to achieve an initial TNF concentration of l and 2 µg/ml.
Measurements of net glucose and lactate production, oxygen tension, and
flow rate were taken every minute for the subsequent 15 minutes.

This

was followed by maximal stimulation of liver glucose production with the
addition of glucagon (1 µM final concentration; Sigma).

As described

above, measurements were taken every minute for the next 15 minutes,
resulting in a total liver perfusion time of 64 minutes.

Upon completion

of the perfusion, liver wet weight was determined for use in the calculation of glucose and lactate production rates and oxygen consumption
rates.
E.

ISOIATED LIVER PARENCHYMAL CELL EXPERIMENTS
1.

Isolation procedure
Parenchymal cells were isolated by a modification of the Berry and

Friend technique (21).

Livers were excised from fed rats and were

perfused in a liver Perfusion-Aeration Apparatus as previously described.
For these studies, however, the perfusate was a calcium-glucose-freeHanks ~·iffer (CGFH; pH=7.4; 137mM NaCl, 5.37mM KCl, 0.34mM NazHP04,
0.44mM KHzP04, 4.17rnM NaHC03, 0.4lmM MgS04-7HzO, 0.49mM MgClz-6HzO)
containing 0.05% collagenase (Type l, Sigma) and 0.10% hyaluronidase
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(Type l, Sigma).

Perfusate was oxygenated continuously with 100% 02 and

was recirculated with a minimum flow rate of 40 ml/min.
After approximately 20 minutes, before any obvious breaks in the
liver capsule were evident, the liver was removed from the system and
placed in an ice cold Nalgene beaker with 50 ml of perfusion fluid.
After chilling for 7 minutes, the liver was cut into extremely small
pieces, was mashed gently, and was filtered through gauze and silk into 2
ice cold 50 ml Nalgene centrifuge tubes.

The resulting cell suspension

was centrifuged (50g x 3 minutes) and was washed 3 times with ice cold
CGFH.

After the final wash, the liver parenchymal cells were resuspended

to 40ml final volume in ice cold KRB containing 2 mg/ml bovine albumin.
Cells were counted with a hemocytomcter and dye exclusion of trypan blue
was used as a measure of cell viability, which ranged from 80-95%.
2.

Incubation conditions
After determining cell number with the hemocytometer, KRB con-

taining 2 mg/ml albumin was added to the cell suspension to adjust the
final cell concentration to 2 x 106 cells/ml.

Cells were placed in 25ml

siliconized (Sigmacote; Sigma) Erlenmeyer flasks, were gassed with 95%
02/ 5% C02 for 1 minute, and then were incubated at 37°C for 60 minutes
in a gently shaking water bath.

Effect of TNF on basal glucose pro-

duction rate was determined by incubating the cells (2.8 ml x 2xl06
cells/ml) with added saline or added TNF (0.01 to 5 µg/ml final concentration); final

in~··~ation

volume was 3 ml.

In order to ascertain the

effect of TNF on hormone stimulated glucose production, cells were
incubated with added saline plus glucagon or saline plus vasopressin (1

µM final concentration), or with added TNF plus glucagon or TNF plus
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vasopressin.

At the end of the indicated incubation time, 200 µl of

sample was removed from each flask and was used for glucose and lactate
measurements.
3.

Glucose

utilizat~on

by isolated hepatocytes

Isolated liver parenchymal cells from fed rats were isolated in
the manner previously described and were resuspended in KRB containing 2
mg/ml albumin, 1 mg/ml D-glucose and 0.1 µCi/ml 1 4 c-glucose (Amersham).
Cells (S ml) were incubated for 2 hours at 37°C in si.liconized metabolic
flasks in the absence or presence of added TNF (0.01 to S µg/ml final
concentration).

After the 2 hour incubation and then the addition of 1

ml of 62.5% citric acid to the incubation media, expired 1 4 co2 was
collected on methylbenzethonium hydroxide (Sigma) saturated filter paper
in scintillation vials for 60 minutes.

After the 60 minute collection

period, liquid scintillation fluor (15 ml; 1 liter toluene, 4 gm PPO, 0.1
gm POPOP) was added to each vial.

Vials were counted in a liquid

scintillation counter for 10 minutes, after a dark adaptation period of
30 minutes.
F.

GLUCOSE AND IACTATE MEASUREMENTS
1.

Glucose determination
A YSI model 23A glucose monitor (Yellow Springs Instrument Co.;

Yellow Springs, OH) was used to determine plasma glucose concentrations
and isolated hepatocyte glucose production.

For isolated perfused liver

experiments, glucose production was dl. Jrmined using a YSI model 26
continuous glucose monitor.
The same operating principles pertain for both machines.
of the glucose probe is covered with a 3-layer membrane.

The tip

The outer layer
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is a P

olycarbonate material which is freely permeable to glucose, oxygen,
.

hydrogen peroxide, water and salt.

The middle layer contains a thin

layer of glutaraldehyde resin in which glucose oxidase is immobilized.
The inner layer consists of a cellulose acetate material which is freely
permeable only to hydrogen peroxide, oxygen, water, and salt.

Hence,

glucose in the sample chamber readily passes through the outer membrane
layer and reacts with the glucose oxidase to produce gluconic acid and
hydrogen peroxide by the following reaction:
gluconic acid+ H202.

D-glucose + 02 --->

A portion of the hydrogen peroxide produced

diffuses through the inner layer and then is oxidized at the platinum
anode:

H202 ---> 2H+ + 02 + 2e·.

Thus, the current produced at the

platinum anode is directly proportional to the amount of hydrogen
peroxide that was generated and had diffused through the inner membrane.
2.

Lactate determination
Lactate concentration (mM) for in vivo and isolated cell experi-

ments were determined with YSI model 23A lactate analyzer.

Online

measurements of lactate produced during isolated perfused liver
experiments were made with a YSI model 26 continuous lactate monitor.
The principles of operation for lactate measurements are similiar
to those for glucose determinations, except that a different membrane
system was used.

In this case, the 3-layer membrane contained an

immobilized L-lactate oxidase and flavin dinucleotide (FAD) between the
outer and inner membranes.

Lactate in the sample char.· "r readily

diffuses through the outer layer and reacts with L-lactate oxidase in the
presence of FAD to produce pyruvate and hydrogen peroxide in the following manner:

lactate

+

02 ---> pyruvate +

H202.

Hydrogen peroxide
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generated in this reaction diffuses through the inner membrane and is
oxidized at the platinum anode.

Thus, the current generated is directly

proportional to the amount of hydrogen peroxide that is generated and
diffuses through tile inner membrane.
G.

INSULIN MEASUREMENTS
Plasma insulin for in vivo experiments was measured using a double

antibody radioimmunoassay (Cambridge Medical Technology Corp.; Billerica,
MA).

This assay had a sensitivity level of 2.0 µU/ml and an interassay

coefficient of variability less than 10%.
H.

NOREPINEPHRINE AND EPINEPHRINE MEASUREMENTS
Plasma norepinephrine and epinephrine levels were determined using a

radioenzymatic assay (Upjohn Diagnostics; Kalamazoo, MI).

A dose of 20

µl of a solution containing EGTA (90 mg/ml) and glutathione (60 mg/ml)
was added to each milliliter of whole blood collected.

The arterial

blood sample was centrifuged, the plasma was removed and then was stored
at -40°C until analyzed.

This assay had a sensitivity of 2 pg/ 50 µl

and an interassay variation of approximately 10%.
I.

CORTICOSTERONE MEASUREMENTS
Plasma corticosterone levels were determined using a double antibody

radioimmunoassay (Radioassay Systems Lab; Carson City, CA).

The

sensitivity of this assay was 2.5 ng/tube and an interassay variation of
6.5%.
J.

PROTEIN DETERMINATION
For each isolated liver parenchymal cell experiment, samples were

taken for protein determination by the Bio-Rad protein assay technique
(Bio-Rad; Richmond, CA).

Protein samples were diluted 1 to 3 in water
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and 100 µl quantities were used to measure protein concentration.

The

color change of Coomassie Brillant Blue G-250 in response to various
concentrations of protein was reflected in 00595 value changes.
albumin (20-140 µg/tube) was used

~o

Bovine

generate the standard curve.

By

linear regression analysis of the bovine albumin standard curve, the
protein content of each experimental sample was determined from its
corresponding 00595 value.
K.

STATISTICAL ANALYSIS
Results are reported as mean ± standard error of the mean

(mean±SEM).

A 2-way ANOVA (treatment, time) with repeated measures

followed by post-hoc analysis (Student Newman-Keuls, Tukey's, or Least
Significant Difference tests) were performed on the in vivo data.
probability tests were performed on the survival data.

Exact

For the isolated

perfused liver experiments, statistical significance was determined by
Student's unpaired t-test.
liver parenchymal cell data.
p$ 0.05.

A 1-way ANOVA was performed on the isolated
In each case, significance was accepted at

CHAPTER IV
RESULTS
A.

IN VIVQ EFFECTS OF TUMOR NECROSIS FACTOR
1.

Experimental groups
Initial experiments were conducted to evaluate the effects of TNF

and ETX in conscious, unrestrained,

fas~ed

cannulated rats.

The fasted

rats were healthy, without any sign of discomfort, before they were
arbitrarily assigned to one of the following eight treatment groups:

1)

saline; 2) H.I.-TNF; 3) 0.1 mg/kg TNF; 4) 0.5 mg/kg TNF; 5) 1.0 mg/kg
TNF; 6) 1.55 mg/kg ETX; 7) 30 mg/kg ETX; or 8) co-treatment with 0.1
mg/kg TNF plus 1.55 mg/kg ETX.

In addition, two groups of fed, can-

nulated, unrestrained conscious rats were treated with either saline or
high dose TNF (1.0 mg/kg).
2.

Mortality and morbidity induced with TNF, ETX, and TNF plus ETX

co-treatment
The mortality rates observed at 4, 6, and 24 hours after an i.v.
bolus injection of saline, H.I.-TNF, TNF (0.1, 0.5, or 1.0 mg/kg), ETX
(1.55 or 30 mg/kg), or TNF plus ETX co-treatment (0.1 + 1.55 mg/kg,
respectively) in fasted rats are presented in table 2.

The fractions

represent the number of animals that died out of the total number of rats
injected for each group.
co~trol

As anticipated, none of the animals in the two

groups died as a consequence of saline or H.I.-TNF injection.

They appeared healthy at the onset of the protocol and remained that way
for the subsequent 24 hours.
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The mortality and morbidity observed after TNF administration were
dose dependent (table 2).

A low dose of TNF, 0.1 or 0.5 mg/kg, resulted

in the death of 1 animal in each group during a 24 hour period.

There

were no deaths in either group early on, even though some of the animals
began to look ill.

When fasted rats were given a higher dose of TNF, 1.0

mg/kg, 4 out of 6 rats died within 4 hours.

An additional rat died by 6

hours, but no additional rats died in the subsequenc 18 hours.

When a 1

mg/kg dose of TNF was injected into fed cannulated rats (table 3) a lower
mortality rate was observed within the first 6 hours as compared to that
observed with fasted cannulated rats given this same dose (table 2):
death was observed at 4 hours, 2 deaths were observed by 6 hours.
death rate by 24 hours was 3 out of 5.

1

The

Rats given TNF manifested ruffled

fur, cyanotic extremities, and labored breathing.
Two groups of animals were treated with different doses of ETX in
order to compare the mortality and morbidity induced with TNF to that
induced with ETX.

Animals given a low dose of ETX, 1.55 mg/kg,

demonstrated a mortality rate at 24 hours that was identical to the
mortality rate observed in rats given a low dose of TNF, 0.1 mg/kg; 1 out
of 5 rats died.

This death occurred within 3 hours after ETX injection,

suggesting that this rat was somewhat more sensitive to ETX than the
others, even though there were no observable signs which indicated such a
difference.

When a much higher dose of ETX was given, 30 mg/kg, 2 deaths

occ·-red within the first 4 hours.

By 6 hours, 2 more rats had died, and

by 24 hours all the rats had died.

These animals demonstrated clinical

signs of illness similar to those observed after a 1 mg/kg dose of TNF:
their fur was ruffled, extremities were cyanotic, and their breathing was
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TABLE 2
TIME AND DOSE DEPENDENT EFFECTS OF TNF- AND ETX.-INDUCED LETHALITY IN
FASTED CANNlJLATED RATS

TREATMENT

DOSE(mg/kg)

4 hours

6 hours

24 hour.;

SALINE

0/11

0/11

0/11

H. I. -TNF

O/S

O/S

O/S

0.1

0/6

0/6

l/S

o.s

0/6

0/6

l/S

1.0

4/6

S/6

S/6

1. SS

l/S

l/S

l/S

30

2/6

4/6

6/6

TNF

ETX

(TNF+ETX)

(0.1+1.SS)

6/6*+

Left carotid artery and right jugular vein cannulae were surgically
implanted 16 hours prior to experimentation. Fasted rats were injected
i.v. with saline (0.l-0.6S ml), heat-inactivated TNF (H.I.-TNF; 0.6S
ml), TNF (0.1, O.S, or 1 mg/kg), ETX (l.SS or 30 mg/kg), or co-treatment
with TNF plus ETX (0.1 + l.SS mg/kg, respectively). *P~ O.OS, low dose
TNF or ETX alone vs. co-treatment with TNF plus ETX; +p~ O.OS, high dose
ETX vs. low dose TNF plus ETX co-treatment.
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TABLE 3
LETHAL EFFECTS OF HIGH DOSE TNF IN FED CANNUIATED RATS

TREATMENT

OOSE(mg/kg)

SALINE
TNF

1.0

4 hours

6 hours

24 hours

0/5

0/5

0/5

1/5

2/5

3/5

Left carotid artery and right jugular vein cannulae were implanted in fed
rats under 5% Halothane. Animals were allowed 4 hours to recover from
surgery before they were given an i.v. bolus injection of saline (0.65ml)
or TNF (l.O mg/kg).
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labored.

These rats, however, also manifested 2 other clinical signs

that were not observed with the TNF treated animals, i.e. porphyrintinged ocular discharge and diarrhea.
Additionally, rats were co-treated with low dose TNF plus low dose
ETX to evaluate the lethal response.

Fasted cannulated rats were given

an i.v. bolus injection of 0.1 mg/kg TNF followed immediately with an
i.v. bolus injection of 1.55 mg/kg ETX.

As reported in table 2, co-

treatment with TNF plus ETX resulted in a mortality rate of 100% within 4
hours.

Co-treatment with TNF plus ETX was significantly more lethal by 4

hours than a bolus injection of a high dose of ETX (30 mg/kg).

Compared

to the mortality rate observed by 4 hours after a high dose of TNF (1
mg/kg), co-treatment with TNF plus ETX was just as lethal if not more so.
This data suggests that the combined effects of a low dose of TNF (0.1
mg/kg) with a low dose of ETX (1.55 mg/kg) may be more detrimental early
on than a highly lethal dose of either agent given alone.
3.

TNF- and ETX- induced mortality after glucan pretreatment
It was hypothesized that an agent which increased an animal's

sensitivity to the lethal effects of ETX, such as glucan, also may
sensitize an animal to the lethal effects of TNF.
tested in the following manner.

This hypothesis was

Fed rats were pretreated with saline or

glucan 72 hours prior to the injection of saline, 0.1 mg/kg TNF, or 1.25
mg/kg ETX (table 4).

Doses of 0.1 mg/kg TNF and 1.25 mg/kg ETX injected

into these rats were sublethal, as indicated by 0% mortality observed for
the saline pretreated groups.

Glucan pretreatment greatly enhanced the

animals' sensitivity to ETX as demonstrated by 7 out of 7 deaths after
the injection of 1.25 mg/kg ETX.

However, animals pretreated with glucan
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TABLE 4
EFFECTS OF GLUCAN PRETREATMENT ON TNF- OR ETX- INDUCED LETHALITY

TREATMENT 1

TREATMENT 2

SALINE

SALINE

GLUCAN

DOSE (mg{kg)

LETHALITY
0/6

TNF

0.1

0/6

ETX

1.25

0/6

SALINE

0/5

TNF

0.1

0/5

ETX

1. 25

7/7*

Rats were injected i.v. either with saline or 10 mg/kg particulate glucan
and returned to their cages with ample food and water. After 72 hours,
they were challenged with saline, TNF (0.1 mg/kg), or ETX (1.25 mg/kg)
and were observed for 24 hours to determine survival. *p~ 0.05
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were not more sensitive to the lethal effects of TNF:

1.25 mg/kg of TNF

was a sublethal dose for the glucan pretreated animals as well as the
saline pretreated animals.

Glucan pretreatment enhanced ETX sensitivity

such that a 24x smaller dose given to rats was just as lethal as a 30
mg/kg dose given to non-sensitized rats.
for TNF:

However, this was not the case

a lOx smaller dose of TNF did not have the same lethal effects

in glucan pretreated rats (table 4) as a 1.0 mg/kg dose had in normal
rats (table 3).
4.

Hemodynamic effects of ETX, TNF, and ETX plus TNF co-treatment:

mean blood pressure
As a simplified index of overall hemodynamic status, mean blood
pressure (MBP) was recorded from the carotid artery cannula of conscious,
unrestrained rats.

MBP was recorded and compared for the following

groups of animals:

1) high dose ETX and high dose TNF treated fasted

rats; 2) low dose ETX and low dose TNF treated fasted rats; and 3) low
dose ETX plus low dose TNF co-treated fasted rats.

High dose TNF was

tested also in fed cannulated rats.
ETX administration resulted in significant modifications of MBP in
fasted animals.

Sixty minutes after a low dose of ETX (l.55 mg/kg), MBP

had dropped to 83 mmHg from a pre-injection level of 128 mmHg (figure 3).
MBP rebounded by 90 minutes to 98 mmHg, even though it was still significantly lower than the saline control MBP.
rats also was significantly lower

~han

The MBP for ETX treated

those for the low dose TNF treated

animals at 60, 90, and 120 minutes, respectively.
Administration of a high dose of ETX (30 mg/kg) to fasted rats
(figure 1) resulted in a significant hypotensive response at 30, 60, and

72
90 minutes post-injection.

MBP dropped to levels of 82, 76, and 88 mmHg

by 30, 60, and 90 minutes, respectively, from a pre-injection level of
127 mmHg.

These pressures at 30, 60, and 90 minutes also were sig-

nificantly lower than those observed in the saline and high dose TNF
treated groups.

By 120 minutes, the ETX-induced hypotension had subsided

and the MBP was up to 106 mmHg, same as the saline control values.
Contrary to the effects observed after ETX, treatment with either
low (0.1 mg/kg; figure 3) or high (1 mg/kg; figure 1) doses of TNF
produced no significant alterations in MBP in fasted rats as compared to
the saline controls.

MBP for the low dose TNF group averaged 117 mmHg

(figure 3) which was consistant with that recorded for the saline control
animals.

A high dose of TNF given to fasted cannulated rats elicited no

observable change in MBP, which averaged 108 mmHg (figure 1).

In fed

rats, however, a 1 mg/kg dose of TNF resulted in a statistically
significant elevation in mean blood pressure to 137 and 131 mmHg at 90
and 120 minutes post-injection, respectively (figure 2).

These values

were significantly higher than 124 and 115 mmHg observed in the saline
control animals at 90 and 120 minutes, respectively.

This was a

transient increase in MBP; by 210 minutes the TNF treated animals had a
MBP identical to the saline controls.
Co-treatment with low dose ETX plus low dose TNF in fasted rats
resulted in a significant depression in MBP within 30 minutes (figure 3).
The MBP remained significantly depressed relative to the saline control
MBP throughout the study.

By 30 minutes, co-treatment with ETX plus TNF

resulted in a significant drop in MBP to 98 mmHg, which was significantly
lower than the saline control value of 118 mmHg.

More importantly,
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FIGURE 1
EFFECTS OF HIGH DOSE TNF AND ETX ON MEAN BIDOD PRESSURE
IN FASTED CANNUIATED RATS

Rats were injected i.v. with either saline (n-3), heat-inactivated TNF
(H.I.-TNF; n-5), 1.0 mg/kg TNF (n-6), or 30 mg/kg ETX (n=6).

Values

reported are mean blood pressures ± SEM (mmHg) in surviving rats.

Mean

pressures reported at 240-330 minutes for the TNF treated group are the
average of 2 values.

The 360 minute value reported for the TNF treated

group is the mean blood pressure in the single surviving rat.

Pressures

reported at 330 and 360 minutes for the ETX treated group represent the
means of 2 values.

ETX.

...:ps 0.05 treatment vs saline.

1f:ps 0.05 TNF vs.

--'V-

H. I. -TNF

~TNF

-e- ETX

**
o--~+--~+--~+-~+-~+-~+-~+-~+-~-+-~-+-~-+-~-+-~-+-~~

0
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&O
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120
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TIME (minutes)
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270

300
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3&0
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FIGURE 2

EFFECTS OF HIGH

~OSE

TNF ON MEAN BLOOD PRESSURE IN FED CANNULA.TED RATS

Rats were given an i.v. bolus iujection of saline (n-5) or 1 mg/kg TNF
(n=5).

Values reported are mean blood pressures± SEM (mmHg) in

surviving rats.

....:p~ 0.05 TNF vs. saline.
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FIGURE 3
EFFECTS OF I.DY DOSE TNF, I.DY DOSE ETX, AND I.DY DOSE TNF PLUS ETX COTREATMENT ON MEAN Bl.DOD PRESSURE IN FASTED CANNUI.ATED RATS

Rats were injected i.v. with either saline (n-7), 0.1 mg/kg TNF (n=6),
1.55 mg/kg ETX (n=4), or co-treatment with 0.1 mg/kg TNF plus 1.55 mg/kg
ETX (n=6).

Values reported are mean blood pressures± SEM (mm.Hg) in

surviving rats .... :ps 0.05 treatment vs saline. ():ps 0.05 ETX vs. TNF.
+:ps 0.05 TNF plus ETX co-treatment vs. TNF.
co-treatment vs. ETX.

():ps 0.05 TNF plus ETX

-*-TNF

-a- ETX
-+- (TNF+ETX)

*+

oL--------+
0 --------3~0--.------~.o~------~.~0--------::12~0:------~
(COHTAOL)

TIME (minutes)
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co-treatment with ETX plus TNF elicited a drop in MBP at 30 minutes which
was significantly lower than the 116 mmHg pressure observed for the low
dose ETX (1.55 mg/kg) treated rats.

Co-treatment with ETX plus TNF

resulted in significantly lower MBP than observed in the low dose TNF
treated rats at 60, 90, and 120 minutes.

Co-treatment with ETX plus TNF

appeared to augment the hypotensive effect of ETX alone at 60, 90 and 120
minutes, even though the pressures were not significantly different
statistically.

Co-treatment with ETX plus TNF also appeared to result in

a slower recovery of MBP than observed after low dose ETX treatment
alone.
5.

Hemodynamic effects of ETX, TNF, and ETX plus TNF co-treatment:

pulse rate
Pulse rates were counted as an indicator of heart rates from the
carotid artery pulsatile blood pressure tracings recorded with a Grass
polygraph.

Pulse rates were counted and compared for the following

groups of conscious, unrestrained rats:

1) high dose ETX and high dose

TNF treated fasted rats; 2) low dose ETX and low dose TNF treated fasted
rats; and 3) low dose ETX and low dose TNF co-treated fasted rats.

Ad-

ditionally, the influence of high dose TNF on pulse rates in fed, conscious rats was evaluated.

Saline treated animals for each treatment

group maintained fairly steady pulse rates throughout the course of these
studies.
~ificant

H.I.-TNF treated rats had a slight but physiologically insigelevation in pulse rate (figure 4).

Dose dependent changes in pulse rate were observed with ETX
treated rats.

A low dose of ETX (l.55 mg/kg) injected into rats resulted

in a transient decrease in pulse rate relative to saline control rats by
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60 minutes (figure 6).

At 90 minutes, the pulse rate in ETX treated

animals was 360 ppm compared to 423 ppm in saline control rats.

This

pulse rate observed in the ETX treated rats at 90 minutes was also
p~m

significantiy lower than the pulse rates of 426

and 415 ppm deter-

mined for low dose TNF and ETX plus TNF co-treated rats,

resp~ctively.

Quite opposite results were observed with rats given a high dose of ETX,
ie. 30 mg/kg (figure 4).

Pulse rates increased from a pre-injection

value of 392 ppm to a peak value of 480 ppm 180 minutes later.

Within 30

minutes after the injection of a high dose of ETX, pulse rates in these
r~ts

increased to 443 ppm, which was significantly higher than the

corresponding pulse rate for saline controls and high dose TNF treated
rats, 361 and 404 ppm, respectively.

By 90 minutes, the tachycardia

induced with ETX was no longer significantly different from that
demonstrated after 1 mg/kg TNF.
A low dose of TNF (0.1 mg/kg) produced no distinguishable changes
in pulse rate (figure 6).
an average rate of 420 ppm.

Mean pulse rates remained relatively steady at
However, a ten fold greater dose of TNF

resulted in significant elevations in pulse rates (figures 4 and 5).

The

tachycardia induced with high dose TNF in fasted, cannulated rats was
evident by 30 minutes and was statistically significant, relative to
saline control rates, by 90 minutes after TNF injection.

Ninety minutes

after TNF (1 mg/kg) injection, the pulse rate was 466 ppm, approximately
100 ppm greater than the saline control rate.

The

to 518 ppm by 180 minutes and remained elevated.

tachycardi~ ~ncreased

A similar profile was

observed with fed rats given 1 mg/kg TNF (figure 5):

TNF-induced

elevation in pulse rate was evident at 30 minutes and continued to
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FIGURE 4
EFFECTS OF HIGH DOSE TNF AND ETX ON PULSE RATE IN FASTED CANNUI.ATED RATS

Rats were injected i.v. with either saline (n=3),

heat-inactivat~d

(H.I.-TNF; n-5), 1.0 mg/kg TNF (n=5), or 30 mg/kg ETX (n=6).

TNF

Values

reported are mean pulses per· minute± SEM (ppm) in surviving rats.
Values reported at 360 minutes for the TNF and ETX treated groups
represent the average of 2 determinations.
saline.

():ps 0.05 TNF vs. H.I.-TNF.

1f:ps 0.05 treatment vs.

j::{:ps 0.05 ETX vs. TNF.
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FIGURE 5

EFFECTS OF HICH DOSE TNF ON PU'....SE RATE IN FED CANNULATED RATS

Rats were given an i.v. bolus injection of saline (n=S) or 1 mg/kg TNF
(n=S).

Values reported are mean pulses per minute± SEM (ppm) measured

in surviving rats.
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FIGURE 6
EFFECTS OF

L(J~l

DOSE TNF, ID\l DOSE ETX, AND IDW DOSE TNF PLUS ETX CO-

TREATMENT ON PUI.SE RATE IN FASTED CANNUIATED RATS

Rats were injected i.v. with either saline (n-7), 0.1 mg/kg TNF (n=6),
1.55 mg/kg ETX (n-4), or co-treatment with 0.1 mg/kg TNF plus 1.55 mg/kg
ETX

(n~6).

Values reported are mean pulses per minute± SEM (ppm)

measured in surviving rats.
ETX vs. TNF.

....:ps 0.05 treatment vs. saline.

():ps 0.05 ETX vs. TNF plus ETX co-treatment.
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increase further during the subsequent 6 hours.

Pulse rates in the fed

rats given TNF increased from a pre-injection rate of 420 ppm to 542 ppm
by 6 hours.

Resultant TNF-induced tachycardia was not the consequence of

contaminating ETX, as demonstrated by the pulse rates reported for H.I.TNF rats in figure 4.

Mean pulse rates determined at 90,

180, and 360

minutes for the high dose TNF treated animals were significantly greater
than the puise rates in H.I.-TNF treated controls.
Co-treatment with low dose ETX plus low dose TNF resulted in
neither an increase in pulse rate as observed after a high dose of ETX or
TNF alone, nor a decrease in pulse rate as observed after a low dose of
ETX alone.

There were no significant changes in pulse rates measured in

low dose ETX plus low dose TNF co-treated.rats relative to both the
respective pre-injection rate of 382 ppm and the saline controls (figure
6).

It appeared that the bradycardia inducing effect of low dose ETX was

obliterated by co-treatment with low dose TNF.
6.

Metabolic effects of TNF, ETX, and TNF plus ETX co-treatment:

plasma glucose
Arterial blood samples were taken from the indwelling carotid
artery cannula of conscious, unrestrained rats in order to assess changes
in plasma glucose concentration as a result of the following treatments:
1) high dose TNF and high dose ETX in fasted rats; 2) low dose TNF and
low dose ETX in fasted rats; and 3) co-treatment with low dose TNF plus
low dose ETX in fasted rats.

The glucoregulatory changes induced by high

dose TNF were assessed also in fed, conscious, unrestrained rats.
The in vivo glucoregulatory effect of TNF was dose dependent.
low dose of TNF (0.1 mg/kg) elicited no measurable changes in plasma

A
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glucose concentrations in fasted rats (figure 9).

However, a significant

glucoregulatory effect was demonstrated with 1 mg/kg TNF in both fasted
and fed rats.

As illustrated in figure 7, a high dose of TNF induced a

slight hyperglycemia, reflected in the increase in fasted plasma glucose
concentrations by 90 minutes.

Plasma glucose concentration increased to

153 mg/dl by 90 minutes, which was significantly greater than the plasma
glucose concentration of 115 mg/dl in the H.I.-TNF group.

It was

postulated that the hyperglycemia-inducing effect of TNF might be better
illustrated in fed rats as opposed to fasted rats.

Therefore, fed

cannulated rats were challenged with a 1 mg/kg dose of TNF, as illustrated in figure 8.

A significant hyperglycemia was measured 60 minutes

after a high dose of TNF:

plasma glucose concentration increased to 195

mg/dl, a significant elevation above the saline control value of 161
mg/dl.
The decrease in plasma glucose concentrations observed 360 minutes
after high dose TNF administration was of a larger magnitude than the
initial increase in plasma glucose observed at 90 minutes (figure 7).
When fasted rats were injected with 1 mg/kg TNF, plasma glucose levels
dropped to 76.3 mg/dl, significantly lower than the 136 mg/dl concentration observed in the saline controls.

The glucose concentration

reported at 360 minutes for high dose TNF treated fasted rats was the
average value obtained from two rats; 133 and 19 mg/dl.
value, 19 mg/dl, was
treatment.

obtain,~

The second

from a rat in the agonal stages after TNF

Similar degrees of hypoglycemia were observed in the fed rats

that died after treatment with 1 mg/kg TNF (data not shown).
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As a comparison to the changes induced by TNF, dose and time
dependent alterations in plasma glucose concentrations induced by ETX
administration are shown in figures 7 and 9.

Rats injected with a low

dose of ETX (1.55 mg/kg) deffionstrated a significant hyperglycemia as
early as 30 minutes after injection, which increased further by 60 and 90
minutes (figure 9).

Plasma glucose concentrations increased to 201, 273,

and 290 mg/dl by 30, 60, and 90 minutes, respectively, after ETX injection.
mg/dl.

By 120 minutes, plasma glucose concentration dropped to 245
These concentrations were significantly higher than the average

glucose concentrations observed for the saline and low dose TNF treated
rats, 126 and 141 mg/dl, respectively.
High dose ETX induced a biphasic change in plasma glucose
concentrations (figure 7).

Plasma glucose concentration almost doubled

by 30 minutes after ETX (30 mg/kg) injection, increasing from a preinjection value of 134 mg/dl to 257 mg/dl.

Peak hyperglycemia induced

with high dose ETX occurred earlier than with low dose ETX:

peak

elevation occurred by 30 and 90 minutes after injection of 30 mg/kg and

1.55 mg/kg of ETX, respectively.

The hyperglycemia elicited by high dose

ETX was followed by significant hypoglycemia at 360 minutes.

Plasma

glucose concentrations at 360 minutes for the two surviving rats were 69
and 64.5 mg/dl.

Analogous to the severe hypoglycemia observed during the

agonal phase after high dose TNF administration, high dose ETX induced a
severe hypoglycemia in the rats that suct · ,1bed to the lethal effects of
ETX (data not shown).
Co-treatment with TNF plus ETX induced changes in plasma glucose
concentration which closely parallel the changes in plasma glucose
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FIGURE 7
EFFECTS OF HIGH DOSE TNF AND ETX ON PIASMA GLUCOSE IN FASTED CANNUI.ATED
RATS

Rats were injected i.v. with either saline (n-4), heat-inactivated TNF
(H.I.-TNF; n-5), 1.0 mg/kg TNF (n-6), or 30 mg/kg ETX (n-6).

Values

reported are mean plasma glucose concentrations ± SEM (mg/dl) in
surviving rats.

Values reported at 360 minutes for the TNF and ETX

treated group represent the average of 2 determinations .
.... :p~ 0.05 treatment vs saline.

--tf:p~ 0.05 ETX vs. TNF.

():p~ 0.05 TNF vs. H.I.-TNF.
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FIGURE 8
EFFECTS OF HIGH DOSE TNF ON PIASMA GLUCOSE IN FED CANNUIATED RATS

Rats were injected i.v. with saline

(n~S)

or 1 mg/kg TNF (n=S).

reported are mean plasma glucose concentrations ± SEM (mg/dl) in
surviving rats.

*:p::5 0.05 TNF vs. saline.
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FIGURE 9
EFFECTS OF LOW DOSE TNF, LOW DOSE ETX, AND LOW DOSE TNF PLUS ETX COTR.EATMENT ON PIASMA GLUCOSE IN FASTED CANNUIATED RATS

Rats were injected i.v. with either saline (n-7), 0.1 mg/kg TNF (n=6),
1.55 mg/kg ETX (n=5), or co-treatment with 0.1 mg/kg TNF plus 1.55 mg/kg
ETX (n-7).

Values reported are mean plasma glucose concentrations± SEM

(mg/dl) in surviving rats. "*'=P~ 0.05 treatment vs saline. ():p~ 0.05 ETX
vs. TNF.

+:p~

0.05 TNF plus ETX co-treatment vs. TNF.
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observed after a low dose of ETX alone (figure 9).

A significant

hyperglycemia was observed as early as 30 minutes after TNF plus ETX cotreatment.

The plasma glucose concentration reported at 30 minutes for

the TNF plus ETX co-treated group, ie. 234 mg/dl, was higher than the 201
mg/dl concentration determined for the low dose ETX treated group, even
though the difference was not statistically significant.

Peak plasma

glucose concentrations occurred 60 minutes after co-treatment; plasma
glucose increased from a pre-injection concentration of 141 mg/dl to 304
mg/dl by 60 minutes.

Plasma glucose concentrations at 90 and 120

minutes, 277 and 209 mg/dl respectively, indicated that the hyperglycemia
induced with TNF plus ETX co-treatment was transient.

Just as observed

during the agonal phases after high dose ETX or high dose TNF treatment,
rats that died after co-treatment with TNF plus ETX had plasma glucose
concentrations as low as 19 mg/dl.
7.

Metabolic effects of TNF, ETX, and TNF plus ETX co-treatment:

plasma lactate
Changes in arterial plasma lactate concentrations of conscious,
unrestrained, cannulated rats were determined for the following treatment
groups:

1) high dose TNF and high dose ETX in fasted rats; 2) low dose

TNF and low dose ETX in fasted rats; 3) co-treatment with low dose TNF
plus low dose ETX in fasted rats.

Additionally, the effect of high dose

TNF on plasma lactate concentration was examined in fed, conscious,
unrestrained, cannulated rats.
Alterations in plasma lactate concentration induced by TNF were
dose dependent.

A low dose of TNF, 0.1 mg/kg, resulted in an insig-

nificant increase in plasma lactate concentration from 0.65 to 1.07 mM by

97

120

minutes post-injection (figure 12).

However, a high dose of TNF (1

mgfkg) induced a significant increase in plasma lactate concentration in
fasted cannulated rats.

By 90 minutes post-injection, plasma lactate had

increased from a pre-injection value of 0.63 to 1.7 mM (figure 10).
Plasma lactate concentrations continued to increase, so that by 180
minutes, plasma lactate concentrations were elevated to 3.79 mM, which
was significantly higher than the corresponding lactate concentrations in
saline and H.I.-TNF treated rats.

At 360 minutes, the plasma lactate

concentration reported for the high dose TNF treated rats was an average
obtained from two rats; 7.85 mM for the dying animal and 0.9 mM for the
24 hour survivor.
Significant hyperlactacidemia was elicited also in fed rats
administered a high dose of TNF.

As shown in figure 11, a significant

hyperlactacidemia was demonstrated as early as 30 minutes after a 1 mg/kg
dose of TNF.

Plasma lactate increased from a pre-injection value of 0.87

to 1.49 mM by 30 minutes.

Plasma lactate concentration continued to

increase and reached 2.30 mM by 360 minutes post-injection.

The

significant hyperlactacidemia produced after a high dose of TNF in fed
rats was not as severe as the hyperlactacidemia produced in fasted rats.
Rats injected with ETX demonstrated similar changes in plasma
lactate concentrations as described for TNF treated animals.

Low dose

ETX induced a statistically significant increase in plasma lactate
relative to saline treated rats by 60 minutes (figure 12).

Lactate

concentrations increased from a pre-injection value of 0.58 mM to 2.6 mM
by 60 minutes.

3

Plasma lactate concentrations continued to increase to

.64 mM by 90 minutes and then remained elevated.

High dose ETX
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administration elicited an even greater hyperlactacidemia than that
observed after low dose ETX (figure 10).

Plasma lactate concentrations

increased significantly from a pre-injection value of 0.58 to 4.35 rnM by
30 minutes post-injection and continued to increase to 5.43 ;n..'1 by 350
minutes.

The plasma lactate concentration reported at 360 minutes was

the average of 2 determinations; 5.65 and 5.20 mM.

Peak hyper-

lactacidemia elicited after a high dose of ETX was similar to that
produced after a high dose of TNF at 180 and 360 minutes.

However, the

initial increase in plasma lactate occurred earlier and to a greater
degree a=ter a high dose of ETX than after a high dose of TNF.
Co-treatment with low dose TNF plus low dose ETX resulted in a
greater hyperlactacidemia than that reported after high dose ETX or high
dose TNF alone.

Plasma lactate increased from a pre-injection con-

centration of 0.73 mM to 1.87 mM by 30 minutes after co-treatment with
low dose TNF plus ETX.

The elevation in plasma lactate produced by TNF

plus ETX co-treatment was significantly greater than the plasma lactate
concentrations observed in saline control and low dose TNF treated rats
at 30 minutes post-injection.

Although the initial increase in plasma

lactate reported after co-treatment with low dose TNF plus ETX was not
significantly different from that observed after a low dose of ETX alone,
by 90 minutes the increase in lactate observed after TNF plus ETX cotreatment was significantly greater than that observed after low dose
ETX.

Plasma lactate concentration increased to 8.72 mM by 120

minute~

after TNF plus ETX co-treatment, which was higher than the values
reported for saline controls, low dose TNF, low dose ETX, and the peak
values reported after treatment with high dose TNF or ETX.
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FIGURE 10
EFFECTS OF HIGH DOSE TNF AND ETX ON PIASMA IAGTATE IN FASTED GANNULATED
RATS

Rats were injected i.v. with either saline (n-4), heat-inactivated TNF
(H.I.-TNF; n-5), 1.0 mg/kg TNF (n-6), or 30 mg/kg ETX (n=6).

Values

reported are mean plasma lactate concentrations ± SEM (mM) in surviving
rats.

Plasma lactate concentrations reported at 360 minutes for the TNF

and ETX treated groups represent the average of 2 values.

1t:ps 0.05 treatment vs saline.
tf:ps 0.05 ETX vs. TNF.

():ps 0.05 TNF vs. H.I.-TNF.
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FIGURE 11
EFFECTS OF HIGH DOSE TNF ON PIASMA IACTATE IN FED CANNUIATED RATS

Rats were given an i.v. bolus injection of saline (n=5) or 1 mg/kg TNF
(n=5).

Values are mean plasma lactate concentrations± SEM (mM) in

surviving rats.

"*'=P~ 0.05 TNF vs. saline.
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FIGURE 12
EFFECTS OF ID\J DOSE TNF, ID\J DOSE ETX, AND ID\J DOSE TNF PUJS ETX COTREATMENT ON Pl.ASMA LACTATE IN FASTED CANNUIATED RATS

Rats were injected i.v. with either saline (n=7), 0.1 mg/kg TNF (n-6),
1.55 mg/kg ETX (n-5), or co-treatment with 0.1 mg/kg TNF plus 1.55 mg/kg
ETX (n-7).

Values reported are mean plasma lactate concentrations± SEM

(mM) in surviving rats.
vs. TNF.

....:ps 0.05 treatment vs saline.

+:ps 0.05 TNF plus ETX co-treatment vs. TNF.
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8.

Endocrine effects of TNF, ETX, and TNF plus ETX co-treatment:

plasma insulin
Arterial blood samples from conscious, unrestrained, cannulated
rats were analyzed to determine the endocrine modulatory effects, as
assessed by changes in plasma insulin concentration, of the following
treatments:

1) high dose TNF and high dose ETX in fasted rats; 2) low

dose TNF and low duse ETX in fasted rats; and 3) co-treatment with low
dose TNF plus low dose ETX in fasted rats.

Moreover, the influence of

high dose TNF on plasma insulin was evaluated also in fed, conscious,
unrestrained, cannulated rats.
The ability of TNF to influence plasma insulin concentrations was
investigated in fasted and fed rats.

Frqm the data in figure 15, it was

difficult to determine if low dose TNF (0.1 mg/kg) had a direct effect on
plasma insulin in fasted rats.

Because the pre-injection plasma insulin

concentration for the TNF treated rats was significantly elevated
relative to the saline control value, the concentration reported 30
minutes after TNF injection was not statistically different from the preinjection control value.

However, the 30 minute value for the TNF

treated rats was significantly greater than the corresponding value
reported for the saline injected rats; 25.3 µU/ml versus 18.8 µU/rnl,
respectively.

Plasma insulin concentrations for the TNF treated animals

were not different from those determined in the saline control rats at
60, 90, and 120 minutes.

When compared to the respective pre-injection

value of 27.5 µU/ml, however, plasma insulin concentrations appeared to
decrease at 90 and 120 minutes as a result of TNF treatment; 18.0 and
14.3 µU/ml, respectively.
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Significant changes in plasma insulin concentration were observed
in fasted and fed rats after treatment with high dose TNF (1 mg/kg).
Plasma insulin concentrations were significantly depressed relative to
the saline controls at 90 and 360 minutes after high dose TNF administration to fasted rats (figure 13).

By 90 minutes, the plasma

insulin concentration determined for the TNF treated animals was approximately half the value determined for the saline treated rats, 12.9
versus 24.5 µU/ml, respectively.

The hypoinsulinemic effect of TNF also

was evident at 360 minutes post-injection:

22.3 versus 10.0 µU/ml for

the saline control and high dose TNF treated rats, respectively.

The

value reported at 360 minutes for the TNF treated group was the average
from two rats; 9.51 and 10.56 µU/ml.

When tested in fed rats, a high

dose of TNF elicited a biphasic change in plasma insulin concentrations
(figure 14).

A significant hyperinsulinemia was reported at 60 minutes,

with plasma insulin concentration elevated to 62.0 µU/ml for the TNF
treated rats.

By 360 minutes, a significant hypoinsulinemia was

demonstrated in the TNF treated group:
dropped to 20.5 µU/ml.

plasma insulin concentration

Hence, a significant TNF-induced hyperinsulinemia

was demonstrated only in fed rats, whereas significant hypoinsulinemia
was observed by 360 minutes post-injection in both fed and fasted rats.
Dose .dependent changes were observed in plasma insulin concentration after ETX administration.
insulin concentration were elicitec
shown in figure 15.

No significant changes in plasma
.fter low dose ETX administration, as

Although the pre-injection plasma insulin con-

centration for the low dose ETX treated rats appeared to be greater than
the values reported for the other groups, the difference was not
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FIGURE 13
EFFECTS OF HIGH DOSE TNF AND ETX ON PIASMA INSULIN IN FASTED CANNUIATED
RATS

Rats were injected i.v. with either saline (n=4), heat-inactivated TNF
(H.I.-TNF; n-5), 1.0 mg/kg TNF (n-6), or 30 mg/kg ETX (n-6).

Values

reported are mean plasma insulin concentrations ± SEM (µU/ml) in
surviving rats.

Plasma insulin concentrations reported at 360 minutes

for the TNF and ETX treated groups represent the average of 2
determinations .... :p~ 0.05 treatment vs saline. ~:p~ 0.05 TNF vs. ETX.
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FIGURE 14
EFFECTS OF HIGH DOSE TNF ON Pl.ASMA INSULIN IN FED CANNUI.ATED RATS

Rats were given an i.v. bolus injection of saline (n-5) or 1 mg/kg TNF
(n=5).

Values reported are mean plasma insulin concentrations± SEM

(µU/ml) in surviving rats.

1c:p~ 0.05 TNF vs. saline.
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FIGURE 15
EFFECTS OF LOW' DOSE TNF, LOW' DOSE ETX, AND LOW' DOSE TNF PLUS ETX COTREATMENT ON Pl.ASMA INSULIN IN FASTED CANNUl.ATED RATS

Rats were injected i.v. with either saline (n=7), 0.1 mg/kg TNF (n=6),
1.55 mg/kg ETX (n-5), or co-treatment with 0.1 mg/kg TNF plus 1.55 mg/kg
ETX (n-7).

Values reported are mean plasma insulin concentrations± SEM
...:ps 0.05 treatment vs saline.
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o. 05

0.05 TNF vs. TNF plus ETX co-treatment.
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(µU/ml) in surviving rats.
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statistically significant.

High dose ETX administration, however,

induced an observable but not statistically significant increase in
plasma insulin concentrations by 30 and 90 minutes relative to the
respective pre-injection control value (figure 13).

A significant

hypoinsulinemia was elicited 360 minutes after a high dose of ETX.

The

plasma insulin concentration reported at 360 minutes for the high dose
ETX treated rats, 3.60 µU/ml, was the average for 2 rats; 3.96 and 3.23
µU/ml.
Co-treatment with low dose TNF plus ETX resulted in a significant
change in plasma insulin which was unlike that reported for rats treated
with either TNF or ETX alone.

No significant alterations in plasma

insulin concentration occurred within the first 90 minutes after cotreatment with TNF plus ETX (figure 15).

By 120 minutes, however, there

was a significant increase in plasma insulin concentration to 34.3 µU/ml,
which was significantly greater than the values reported for the saline
control, low dose TNF, and low dose ETX treated groups; 15.7, 14.3, and
20.1 µU/ml, respectively.
9.

Neuro-endocrine effects of TNF:

plasma catecholamines

The effects of high dose TNF on plasma epinephrine and norepinephrine concentrations were evaluated in fasted, conscious, unrestrained, cannulated rats.

Saline treated rats had no measurable

changes in plasma epinephrine or norepinephrine concentrations; plasma
epinephrine and norepinephrine remained steady thrc,<,hout the experiment
at average mean values of 72.l and 82.l pg/ml, respectively.

Because

changes in plasma epinephrine and norepinephrine concentrations are
sensitive indicators of stress, the failure to demonstrate a significant
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FIGURE 16
EFFECTS OF HIGH DOSE TNF ON PIASMA EPINEPHRINE IN FASTED CANNULATED RATS

Rats were injected i.v. with either saline (n=3), heat-inactivated TNF
(H.I.-TNF; n=4), or 1.0 mg/kg TNF (n=6).

Values reported are mean plasma

epinephrine concentrations± SEM (pg/ml) in surviving rats.

The value

reported at 360 minutes for the TNF treated group represents the average
of 2 determinations.
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FIGURE 17
EFFECTS OF HIGH DOSE TNF ON PIASMA NOREPINEPHRINE IN FASTED CANNULATED
RATS

Rats were injected i.v. with either saline (n-3), heat-inactivated TNF
(H.I.-TNF; n=4), or 1.0 mg/kg TNF (n-6).

Values reported are mean plasma

norepinephrine concentrations ± SEM (pg/ml) in surviving rats.

The value

reported at 360 minutes for the TNF group represents the average of 2
values.
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elevation in their concentrations after saline injection supported the
belief that the experimental procedure per se was not stressing the
animals.
Significant elevations in plasma epinephrine and norepinephrine
concentrations occurred by 90 minutes after high dose TNF administration.
Plasma epinephrine increased to 3509 pg/ml from a pre-injection value of
116 pg/ml (figure 16).

Peak elevation in plasma epinephrine was de-

monstrated at 180 minutes with a value of 8004 ± 3674 pg/ml.
minutes, only 2 animals remained:

By 360

the 24 hour survivor had a plasma

epinephrine concentration of 459 pg/ml, whereas the dying animal had a
value of 11587 pg/ml.

Plasma norepinephrine concentrations increased

significantly from a pre-injection value of 120 pg/ml to 1374 pg/ml by 90
minutes after high dose TNF administration (figure 17).
concentrations continued to increase to 3042
and 360

minut~s,

respectively.

Norepinephrine

± 1528 and 4039 pg/ml by 180

The value reported at 360 minutes was the

average of 2 determinations; 544 pg/ml determined for the 24 hour
survivor and 7534 pg/ml determined for the agonal stage rat.
10.

Endocrine effects of TNF:

plasma corticosterone

Plasma corticosterone concentrations were measured after high dose
TNF treatment in fed, conscious, unrestrained, cannulated rats (figure
18).

Saline. injected rats had no measurable change in plasma corti-

costerone concentration; mean plasma corticosterone concentration
averaged 196 ng/ml.

However, high dose -.-p induced a significant in-

crease in plasma corticosterone:

by 30 minutes, plasma corticosterone

increased to 400 ng/ml versus 230 ng/ml for the saline control rats.

TNF

treated animals maintained significantly elevated plasma corticosterone
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FIGURE 18
EFFECTS OF HIGH DOSE TNF ON PLASMA CORTICOSTERONE IN FED

C~lJIATED

Rats were injected i.v. with saline (n=S) or 1 mg/kg TNF (n=S).

RATS

Values

reported are mean plasma corticosterone concentrations ± SEM (ng/ml) in
surviving rats.
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concentrations relative to saline treated animals for 360 minutes.

Final

plasma corticosterone concentrations were 563 ng/ml in the TNF treated
group and 168 ng/ml in saline treated controls.
B.

IN VITRO EFFECTS OF TNF:

ISOI.ATED PERFUSED RAT LIVERS

TNF induced significant alterations in plasma glucose concentration
comparable to those induced after ETX administration in conscious, cannulated rats (figure 8).

These observations suggested that the changes

in hepatic glucoregulation observed after ETX administration might be
mediated by endogenous TNF, released from ETX-activated Kupffer cells,
directly influencing neighboring hepatocyte function.

To evaluate this

hypothesis initially, TNF was tested for direct hepatic glucoregulatory
effects using the isolated perfused rat liver model.

Livers were excised

from fed male rats under sodium pentobarbital anesthesia and perfused in
a recirculating liver perfusion apparatus with glucose-free K.RB containing 2 mg/ml albumin, as described in chapter III.

Because the

perfusion buffer was glucose-free, the glucose concentration measured in
the buffer during the perfusion was the net result of hepatic glucose
mobilization from endogenous stores of glycogen.
The liver was allowed to stabilize in the perfusion system for 30
minutes.

During that time, net hepatic glucose production stimulated by

the absence of glucose in the perfusion buffer and oxygen consumption
reached steady state levels of 92.6 µmoles glucose/gm liver wet weight/
hour and 56.4 µl of oxygen/gm liver wet weight/minute, respectively.
As reported in table 5, the direct effect of TNF on net liver
glucose production rates was examined using the isolated perfused rat
liver model.

Control glucose production rates determined at 30 minutes
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were similar for each group of livers; 94.2, 93.0, and 90.7 µmoles of
glucose/gm liver wet weight/ hour.

At 31 minutes, either 1 ml of PBS

(n-6), 150 µg of TNF (n=5), or 300 µg TNF (n=4) was added directly to the
perfusion reservoir.

During the subseqeunt 15 minutes of perfusiou,

there was a slight reduction in glucose production rate observed in the
PBS treated livers:

net glucose production rate decreased from a value

of 94.2 to 72.S µmoles glucose/gm liver wet weight/hour by 46 minutes.
Livers administered 150 µg of TNF (1 µg/ml final concentration) demonstrated a greater reduction in net glucose output by 46 minutes than was
observed for the PBS treated livers.

After 15 minutes of perfusion with

1 µg/ml TNF, net glucose production rate dropped to 56.6 µmoles glucose/
gram liver wet weight/hour, which appeared to be lower than the rate
reported for the PBS treated controls

(p~0.10).

In order to pursue further the possibility that TNF might directly
modulate hepatic glucose production, livers were challenged at 46 minutes
with a maximal stimulatory dose of glucagon (1 µM final concentration).
As reported in table 5, net glucose production rate increased approximately 4 fold for the PBS treated control group to 294 µmoles glucose/gm
liver wet weight/hour.

Glucagon challenge of the TNF (1 µg/ml) treated

livers resulted in an increase in net glucose production rate to 202
µmoles glucose/gm liver wet weight/hour, which was less than that observed with the PBS treated livers

(p~

0.10).

The basal and glucagon stimulated net glucose production rates for
livers perfused with 1 µg/ml TNF suggested that a higher dose of TNF
might significantly

(p~0.05)

modulate net hepatic glucose production.

Therefore, a group of livers was tested in the same manner as

j~st
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TABLE 5

EFFECTS OF TNF ON GLUCOSE PRODUCTION RATES
BY ISOLATED PERFUSED RAT LIVERS

CONTROL

_N_

TREATMENT

BASAL

GLUCAGON
(1 uM)

94.2±10

6

PBS

93.0±6.7

5

90.7±18

4

72. 8±5 .1

294±23

TNF( lµg/ml)·

56.6±6.3*

202±39*

TNF(2µg/ml)

65.5±9.3

222±46

Values reported are mean net glucose production rates ± SEM by isolated
perfused rat livers (µmoles glucose/gm liver wet weight/hour). Livers
were excised from pentobarbital anesthetized rats and were perfused with
KRB + 2 mg/ml albumin. The control values represent the net glucose
production rates after 30 minutes of perfusion. Either PBS (1 or 2 ml)
or TNF (150 or 300 µg) was added directly to the perfusion reservoir
after 31 minutes of perfusion. After 46 minutes of perfusion, maximum
glucose production was achieved with the administration of glucagon (1 µM
final concentration). Total perfusion time was 64 minutes. *p~ 0.10 TNF
VS PBS.
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described except that a 2 fold greater dose of TNF was added directly to
the perfusion reservoir after 31 minutes of perfusion, ie. 300 µg.
However, there was no significant difference between the net glucose
production rate of TNF treated livers (2 µg/ml) and PBS treated livers;
65.5 vs. 72.8 µmoles glucose/gm liver wet weight/hour, respectively.
Furthermore, TNF treatment (2 µg/ml) failed to alter the glucagon
stimulated increase in net hepatic glucose production.

After challenge

with 1 µM glucagon for 15 minutes, net glucose production rates increased
to 222 µmoles glucose/gm liver wet weight/hour in the TNF treated livers,
which was not significantly different from the rate reported for the PBS
treated livers, 294 µmoles glucose/gm liver wet weight/hour.
Net hepatic lactate production was continuously monitored during the
perfusion and the calculated rates are reported in table 6.

Net lactate

production rates determined during the 30 minute control period were
similar for all 3 groups of livers; 26.3, 20.9, and 11.5 µmoles lactate/
gram liver wet weight/hour, respectively.

Perfusion with 1 or 2 µg/ml of

TNF for 15 minutes did not influence net lactate production rates.

The

rates determined after 15 minutes of treatment with 1 and 2 µg/ml TNF,
24.0 and 21.l µmoles lactate/gm liver wet weight/hour, were not significantly different from the rate reported for the PBS treated group,
17.7 µmoles .lactate/gm liver wet weight/hour.

After challenge with 1 µM

glucagon, livers removed lactate from the perfusate rather than release
lactate into the perfusion buffer.

Thereft

~.

net lactate uptake rates,

presented as negative values for net lactate production rates, are
reported in table 6.

TNF treatment did not influence hepatic lactate

uptake in response to 1 µM glucagon.

Fifteen minutes after challenge
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TABLE 6

EFFECTS OF TNF ON IACTATE PRODUCTION RATES
BY ISOIATED PERFUSED RAT LIVERS

CONTROL

_N_

TREATMENT

BASAL

GLUCAGON

___ll-1!!1.L
26.3±5.6

6

20.9±10

5

11. 5±17

4

PBS

17.7±7.5

-12.7±6.7

TNF(lµg/ml)

24.0±12

-13.1±5.9

TNF(2µg/ml)

21.1±3.9

-14.9±8.3

Values reported are mean net lactate production rates ± SEM by isolated
perfused rat livers (µmoles lactate/gm liver wet weight/hour). The
addition of glucagon resulted in a net uptake of lactate by the livers
as indicated by the negative values.
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TABLE 7
EFFECTS OF TNF ON OXYGEN CONSUMPTION RATES
BY ISOLATED PERFUSED RAT LIVERS

CONTROL

_N_

TREATMENT

BASAL

GLUCAGON
(1 uM)

58.3±3.0

6

57.4±2.6

5

53.6±2.5

4

PBS

59.8±2.8

62.9±4.2

TNF(lµg/ml)

58. 1±1. 2

60. 8±1. 9

TNF(2µg/ml)

57.6±2.7

60. 2±1. 7

Values reported are mean net oxygen consumption rates ± SEM by isolated
perfused rat livers (µl of oxygen/gm liver wet weight/min). Liver oxygen
consumption rates were calculated from the difference in oxygen
saturation of the perfusion fluid going into and coming out of the
perfused liver.
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with 1 µM glucagon, net lactate uptake rates were 12.7, 13.1, and 14.9
µmoles lactate/gm liver wet weight/hour for PBS, 1 and 2 µg/ml TNF
treated livers, respectively.
I~

addition to net hepatic glucose and lactate production, liver

oxygen consumption was measured during the perfusion, as discussed in
chapter III.

During the control period, liver oxygen consumption rates

were similar for each group of livers:
liver wet weight/minute, table 7.

58.3, 57.4, and 53.6 µl oxygen/gm

After 15 minutes of continuous per-

fusion with 1 or 2 µg/ml TNF, there was no measurable change in oxygen
consumption rate relative to the control rate determined for PBS treated
livers.

The slight increase in oxygen consumption rate observed after

challenge with 1 µM glucagon was not altered by treatment with TNF.
Fifteen minutes after challenge with 1 µM glucagon, oxygen consumption
rates reported for PBS, 1 µg/ml TNF, and 2 µg/ml TNF treated livers were
62.9, 60.8, and 60.2 µl oxygen/gm liver wet weight/minute, respectively.
There were no other observable changes in livers perfused with 1 or
2 µg/ml TNF.

Flow rate to the livers remained steady at 50 ml/minute for

both PBS and TNF treated livers.

The outward appearance of the livers

during perfusion with 1 or 2 µg/ml TNF was unaltered:

there was no

hepatic swelling or discoloration after TNF administration.
C.

IN VITRO EFFECTS OF TNF:

ISOLATED LIVER PARENCHYMAL CELLS

As a final step in determining the direct, short-term, hepatic
glucoregulatory ef:! ;ts of TNF, isolated hepatocytes from fed rats were
incubated with various doses of TNF.

Unlike the isolated perfused liver

model, hepatocytes were in direct contact with TNF without significant
interference from other non-parenchymal liver cells, such as Kupffer
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cells and endothelial cells.

Furthermore, the dose dependent influence

of TNF on hepatic glucoregulation was easily evaluated with the cells
isolated from each individual liver, rather than different cell
preparations for each dose of T,fF tested.
TNF at doses of 0.01-5.0 µg/ml had no effect on net glucose
production rates, as reported in table 8.

Basal rates of glucose

production in ttc presence of 0.01-5.0 µg/ml TNF averaged 0.970 µmoles
glucose/mg protein/hour, which was not significantly different from the
basal rate of 0.939 µmoles glucose/mg protein/hour reported for the PBS
treated control cells.

Just as done with the isolated perfused livers,

isolated hepatocytes were maximally stimulated with 1 µM glucagon to
determine if TNF treatment modulated the hormonal response.

Glucose

production stimulated by the cAMP-dependent hormone glucagon was tested
in cells incubated with PBS or 0.01-5.0 µg/ml TNF (table 8).

PBS treated

control cells stimulated with 1 µM glucagon demonstrated an increase in
net glucose production rate to 1.45 µmoles glucose/mg protein/hour from a
basal rate of 0.939.

TNF treatment failed to modify the cellular

response to 1 µM glucagon, as reflected by the net glucose production
rates.

The average glucose production rate observed with hepatocytes

stimulated with 1 µM glucagon in the presence of 0.01-5.0 µg/ml TNF was
1.39 µmoles glucose/mg protein/hour, a rate not significantly different
from the control rate of 1.45 reported for the PBS treated cells.
Since hepatic glucose production also is stimulated by a ca++_
dependent pathway as well as a cAMP-dependent pathway, the ca++_dependent
glucoregulatory hormone, vasopressin, was tested in PBS and 0.01-5.0
µg/ml TNF treated cells.

Under the same conditions as just described,
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TABLE 8
EFFECTS OF TNF ON BASAL AND GLUCAGON-STIMUIATED GLUCOSE PRODUCTION RATES
BY ISOLATED HEPATOCYTES

TREATMENT

DOSE (ug/ml)

PBS

BASAL

GLUCAGON (1

0.939±0.040

1.45±0. 28

uM)

TNF

5

0.975±0.082

1. 42±0. 27

TNF

1

0.963±0.071

1. 44±0. 28

TNF

0.5

0.958±0.064

1.41±0.28

TNF

0.1

0.951±0.074

1. 38±0. 29

TNF

0.05

0.986±0.11

1. 38±0. 27

TNF

0.01

0.986±0.10

1. 33±0. 28

Values reported are mean net glucose production rates ± SEM determined
from four different cell preparations (µmoles glucose/mg protein/hr.).
For each preparation, cells were isolated and incubated in triplicate for
60 minutes at 37°C in KRB + 2 mg/ml albumin in the absence or presence of
the indicated doses of TNF ± glucagon.
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TABLE 9

EFFECTS OF TNF ON BASAL AND VASOPRESSIN - STIMUIATED GLUCOSE PRODUCTION
RATES BY ISOLATED HEPATOCYTES

TREATMENT

DOSE (ug;Lml}

BASAL

VASOPRESSIN
(1 uM}

PBS

0.681±0.021

0.780±0.078

TNF

5

0.650±0.046

0.767±0.072

TNF

1

0.592±0.011

0.794±0.079

TNF

0.5

0.647±0.054

0.774±0.065

TNF

0.1

0.644±0.059

0.743±0.072

TNF

0.05

0.607±0.048

0.759±0.073

TNF

0.01

0.644±0.053

0.780±0.072

Values reported are mean net glucose production rates ± SEM for three
separate cell preparations (µmoles glucose/mg protein/hr). For each
preparation, cells were isolated and were incubated in triplicate for 60
minutes at 37°C in KRB + 2 mg/ml albumin in the absence or presence of
the indicate"d doses of TNF ± vasopressin.
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TNF had no effect on the basal rate of glucose production by isolated
hepatocytes (table 9).

The average glucose production rate in response

to TNF was 0.631 µmoles glucose/mg protein/hour, which was not significanLly different from the PBS control rate cf 0.681 µmoles glucose/mg
protein/hour.

In response to maximal stimulation with l µM vasopressin,

PBS treated control cells and TNF treated cells responded similarly, as
assessed by net hepatic glucose production rates.

Glucose production

rates increased to 0.780 and an average value of 0.770 µmoles glucose/mg
protein/hour for PBS treated and TNF treated cells, respectively.

Hence,

under short-term conditions, TNF failed to directly influence hepatic
glucoregulation under both basal and hormone stimulated conditions.
In conjunction with evaluating the direct effects of TNF on net
hepatic glucose production, TNF also was evaluated for a direct effect on
net lactate production by isolated hepatocytes.

As reported in table 10,

TNF did not influence the basal rate of lactate production by isolated
hepatocytes.

The average rate of lactate production under the influence

of TNF was 0.354 µmoles lactate/mg protein/hour, which was insignificantly different from the PBS control rate of 0.343 µmoles lactate/mg
protein/hour.

Similar to the results obtained with the isolated perfused

liver model, stimulation with l µM glucagon blunted the net lactate
production by isolated hepatocytes.

In the presence of l µM glucagon,

net lactate production rate dropped to 0.073 µmoles lactate/mg protein/
hour from a basal value of 0. 343 µmoles lactate/mg protein1:1our for the
PBS treated control cells.

And just as observed with the isolated

perfused livers, TNF treatment did not interfere with the hepatocytes'
ability to use lactate as a gluconeogenic substrate after stimulation
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TABLE 10
EFFECTS OF TNF ON I.ACTATE PRODUC/rION RATES BY ISOI.ATED HEPATOCYTES

TREATMENT

DOSE (ug/ml)

PBS

BASAL

GLUCAGON

(luM)

0.343±0.050

0.073±0.005

TNF

5

0.333±0.050

0.085±0.006

TNF

1

0.333±0.040

0.093±0.016

TNF

0.5

0.350±0.051

0.098±0.018

TNF

0.1

0.365±0.046

0.133±0.050

TNF

0.05

0.373±0.037

0.073±0.012

TNF

0.01

0.370±0.071

0.113±0.040

Values reported are mean net lactate production rates ± SEM for four
separate cell preparations (µmoles lactate/mg protein/hr). For each
preparation, cells were isolated and were incubated in triplicate for 60
minutes at 37°C in KRB + 2 mg/ml albumin in the absence or presence of
the indicated doses of TNF ± glucagon.
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TABLE 11
EFFECTS OF TNF ON I.ACTATE PRODUCTION RATES BY ISOI.ATED HEPATOCYTES
IN THE ABSENCE OR PRESENCE OF VASOPRESSIN

TREATMENT

DOSE {ugLml)

BASAL

VASOPRESSIN
{luM)

PBS

0.244±0.053

0.358±0.092

TNF

5

0.276±0.022

0. 321±0. 066

TNF

1

0.215±0.063

0.287±0.048

TNF

0.5

0.301±0.038

0.323±0.007

TNF

0.1

0.232±0.053

0.307±0.072

TNF

0.05

0.217±0.044

0.319±0.065

TNF

0.01

0.270±0.070

0.323±0.052

Values reported are mean net lactate production rates ± SEM for three
separate cell preparations (µmoles lactate/mg protein/hr). For each
preparation, cells were isolated and were incubated in triplicate in KRB
plus 2 mg/ml albumin for 60 minutes at 37°C in the absence or presence of
the indicated doses of TNF ± vasopressin.
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TABLE 12 ·

EFFECTS OF TNF ON GLUCOSE UTILIZATION BY ISOLATED HEPATOCYTES

TREATMENT

DOSE (ug/ml)

GLUCOSE OXIDATION
333±54

CONTROL
TNF

5

344±15

TNF

1

341±55

TNF

0.5

354±52

TNF

0.1

338±27

TNF

0.05

356±27

TNF

0.01

298±18

Values reported are mean 14c counts ± SEM from four separate cell
preparations (DPM/mg protein). For each preparation, cells were isolated
and were incubated in triplicate for 120 minutes at 37°C in KRB containing 2 mg/ml albumin, 1 mg/ml D-glucose, and 0.1 µCi/ml 14c-D-glucose
in the absence or presence of TNF. Expired 14co2 was collected for 60
minutes on methlybenzethonium hydroxide saturated filter paper after the
addition of 62.5% citric acid.
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with glucagon (table 10).

Hepatocytes treated with 0.01-5.0 µg/ml TNF

responded to the glucagon challenge in a manner similar to the PBS
treated control cells.

Net lactate production rates dropped as a result

of glucagon-stimulated hepatic uptake to an average value of 0.099 µmoles
lactate/mg protein/hour for the TNF treated hepatocytes, which was not
significantly different from the rate of 0.073 µmoles lactate/mg protein/
hour

repor~ed

for the control cells.

Moreover, TNF also failed to

influence the net lactate production rate of hepatocytes stimulated with
1 µM vasopressin (table 11).

Just as reported in table 10, TNF did not

modulate the basal lactate production rate reported in table 11.

The

average net lactate production rate in the presence of 0.01-5.0 µg/ml TNF
was 0.252 µmoles la9tate/mg protein/hour, which was not different from
the control value of 0.244 µmoles lactate/mg protein/hour.

TNF also

failed to alter the net lactate production rate determined after treatment with 1 µM vasopressin.

Net lactate production rates determined in

the presence of 1 µM vasopressin were 0.358 for PBS treated cells and an
average rate of 0.313 µmoles lactate/mg protein/hour for the TNF treated
cells.
Finally, TNF was tested to determine if its direct hepatic glucoregulatory influence was on hepatocyte glucose utilization rather than
net glucose or lactate production.

Since net hepatic glucose and lactate

production are crude indices of more subtle cellular changes, TNF was
evaluated for a dose dependent influence on glucose oxidation by isolated
hepatocytes.

Hepatocytes were incubated for 2 hours x 37°C in KRB

containing 2 mg/ml albumin, 1 mg/ml D-glucose, 0.1 µCi/ml 14c-glucose and
either PBS or 0.01-5.0 µg/ml TNF.

Released 1 4 co2 was collected for 1
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hour as a measure of 14 c-glucose oxidation.

As reported. in table 12, TNF

did not significantly influence glucose utilization by isolated hepatocytes.

The DPM/mg protein released by PBS treated control cells was 333,

which was not significantly different from the average value of 338
DPM/mg protein reported for the TNF treated groups.

CHAPTER V
DISCUSSION
A.

IN VIVO EVALUATION OF TNF AS A MEDIATOR OF ENDOTOXIC SHOCK
This study compared select pathophysiological changes observed after

comparably lethal, i.v. bolus injections of ETX vis-a-vis TNF in unanesthetized, unrestrained, cannulated rats.
for a number of reasons.

This modai was implemented

First, conscious, unrestrained, cannulated

adult rats were used so that hemodynamic monitoring and blood samplings
were easily obtained and analyzed without the use of anesthesia during
the experimental protocol.

Secondly, since exogenous ETX results in a

"spike-like" increase in endogenous plasma TNF concentrations (103,174),
exogenous TNF was administered as an i.v. bolus injection such that peak
blood levels of exogenous TNF were reached quickly (31,82) and were
followed by a rapid decline (31,82).

Although a continuous infusion of

exogenous TNF achieves the level in plasma TNF elicited after exogenous
ETX administration (175), the rise and subsequent decline in plasma TNF
concentration are slower.

Since both the magnitude of TNF release

(103,224) as well as the duration (127) of the spike may be important in
the severity of the TNF insult, an i.v. bolus injection of exogenous TNF
was used for this study rather than a continuous infusion.

Additionally,

the doses of exogenous TNF administered resulted in levels of plasma TNF
comparable to those measured after an ETX

challen~e.

Lssuming that

exogenous TNF is confined to the extracellular space (82), high dose TNF
(1.0 mg/kg) administered to 350 gram rats resulted in a calculated
137
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initial plasma TNF concentration equivalent to 5 µg/ml, which was similar
to the 5.5 µg/ml TNF produced in vivo in BCG-primed rabbits stimulated
with ETX (1).

Low dose TNF (0.1 mg/kg) administration resulted in a

calculated initial plasma concentration of 0.5 µg/ml, which was greater
than the sub-nanogram per milliliter peak concentrations reported for
humans either infused with non-lethal doses of TNF (175) or given a nonlethal bolus injection of ETX (103,174).

Sub-microgram per milliliter

peak concentrations were observed in baboons (103) and rabbits (161)
following a lethal injection of Escherichia coli and ETX, respectively.
1.

Mortality and morbidity comparisons
Comparison between the pathophysiological changes induced by ETX

and TNF in vivo demonstrated important similarities as well as salient
differences.

Both TNF and ETX had dose dependent lethal effects in

conscious, unrestrained, cannulated rats; however, on a milligram per
kilogram basis, rats were more sensitive to the lethal effects of TNF
than the lethal effects of ETX.

TNF at doses of 1 and 1.8 mg/kg resulted

in mortality rates of 83% in 24 hours (table 2) and 64% in 12 hours
(249), respectively.

Comparable doses of ETX, ie. 1.55 mg/kg, produced

only a 20% mortality in 24 hours; a 30 mg/kg dose of ETX was required for
100% mortality rate during 24 hours.

When rats were pretreated with

glucan, which enhanced the reticuloendothelial system (78), sensitivity
to the lethal effects of ETX increased whereas sensitivity to the lethal
effects of TNF remained unaltered.

The differential sensitivity to TNF

and ETX under normal and RES stimulated conditions provide useful insights in the pathogenesis of endotoxic shock.

Since greater quantities

of TNF are presumably released in response to ETX challenge under RES
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stimulated conditions than under normal conditions, the enhanced sensitivity to ETX observed after glucan pretreatment is correlated with the
enhanced TNF activity.

Failure to demonstrate an augmentation in the

sensitivity to TNF under RES stimulated conditions suggests that the
pathological changes elicited by TNF were not mediated through TNF
stimulated macrophage cytotoxicity (202) or mediator secretion (12,38,
67).

Other agents, such as actinomycin D (34,46) and D-galactosamine

(145) which interfere with cellular function rather than stimulate the
RES, increase the sensitivity to both ETX and TNF, therefore supporting
the hypothesis that the lethal effects induced by ETX and TNF are
related.
The dose dependent morbidity incblced by TNF and ETX was
indistinguishable:

rats exhibited piloerection, labored breathing,

hunched-over posture, and progressive cyanosis subsequent to either ETX
or TNF injection.

Diarrhea was consistently observed in the ETX treated

rats but not in the TNF treated rats, even though TNF-induced diarrhea
had been reported by other investigators (13,125,214,249).

These

symptoms in rats are analogous to the flu-like symptoms, such as chills,
headache, myalgia, nausea, and fever, reported by humans given either a
bolus injection of ETX (174,175) or an infusion of TNF (175).
Neutralization of endogenous TNF by either rabbit antiserum (26)
or specific monoclonal antibodies (250) reduced the lethal effects of ETX
anc

1

ive gram negative bacteria.

Furthermore, the inability to produce

TNF in response to an ETX challenge likewise reduces the mortality and
morbidity associated with lethal endotoxicosis.

For instance, endotoxin-

resistant mice fail to produce TNF in response to an ETX challenge as a
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result of pre- and post-translational defects (24).

Moreover, the

therapeutic effect of steroid treatment prior to an ETX challenge is
related to the steroid-induced block in macrophage TNF production (24).
These findings indeed implicate a role for endogenoils TNF in the
mortality and morbidity observed
2.

Hemodynamic comparisons:

durin~

endotoxicosis and septic shock.

mean blood pressure and pulse rate

Even though comparably lethal doses of ETX and TNF were used in
this study, the pattern of blood pressure changes induced by each agent
differed.

ETX repeatedly produced a significant hypotensive response,

both in this study and in other studies (107,116).

TNF, on the other

hand, did not produce any significant change in MBP as demonstrated in
this study using conscious rats and in other studies using phase I cancer
patients (31,276) or conscious rats administered a non-lethal dose of TNF
(13).

In contrast, studies performed by other investigators using

anesthetized dogs (253) and rats (249) demonstrated significant TNFinduced hypotension.

Since anesthesia is known to interfere with

cardiovascular function, the hypotension observed after TNF administration in anesthetized animals suggests that the response to TNF was
altered by the state of the animals.
Even though TNF did not significantly alter MBP under conscious
conditions, TNF did induce a significant tachycardia in conscious rats.
Similarly, previous studies have demonstrated a significant elevation in
heart rate after peak blood TNF levels were reached subsequent to __ 1 ETX
injection (174,175) or during a continuous infusion of TNF (175) in
conscious humans.

The tachycardia-inducing property of TNF implicates

TNF as a mediator of the persistant tachycardia observed in ETX treated
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rats long after the MBP returned to control levels after the initial
hypotensive response.
Thus, a comparison between the hemodynamic changes induced by ETX
and those induced by TNF suggest the following:

1) the transient hypo-

tension elicited by ETX is not mediated by endogenously produced TNF
since exogenous TNF did not elicit a hypotensive response; and 2) the
persistant

ta~hycardia

observed in ETX treated rats long after the MBP

has returned to control values is possibly mediated by endogenously
produced TNF.
3.

Metabolic ..:omparisons:

plasma glucose and lactate

Both ETX and TNF elicited an initial hyperglycemia.
initial

hyperglycem~a

However, the

observed during endotoxicosis (73,106,137,282) most

likely is not mediated by the hyperglycemia-inducing ability of TNF
(125,249).

This conclusion is based on the following observations.

First, the hyperglycemia induced by ETX occurred more rapidly than the
rise in plasma glucose induced by exogenous TNF.

Second, the hyper-

glycemia induced with high dose TNF was only a fraction of the hyperglycemia elicited by both low and high dose ETX.

Since the TNF induced

effects are delayed and reduced compared to those induced by ETX, it is
unlikely that endogenous TNF mediated the ETX induced hyperglycemia.
Third, the increase in plasma glucose observed after ETX administration
occurred coincident with rather than subsequent to the production of
endogenous TNF (28,90,95,103,161,174,175,266).

Although the hyper-

glycemia inducing property of TNF probably was not involved in the
initial hyperglycemia of endotoxicosis, it might be involved in delaying,
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but not preventing, the hypoglycemia which is observed late in the course
of endotoxlcosis.
More dramatic was the profound hypoglycemia demonstrated during
both ETX- and TNV-induced shock (figure 7).

Rats that succumbed to the

lethal effects of ETX (73,77,106,137,187,282) and TNF (16,125,249) did so
with accompanying hypoglycemia and convulsive episodes.

It may be that

endogenous TNF is responsible for the hypoglycemic effect of ETX either
by interfering with hepatic glucose production through modulation of
glycogenolysis and/or gluconeogenesis or by enhancing glucose utilization.

The direct effect of TNF on hepatic glucoregulation will be

discussed in section C.

However, TNF may participate in enhanced

peripheral glucose utilization by increasing glucose uptake (142) and
utilization by muscle (142) and macrophage-rich tissues (173).

Moreover,

since chronic exposure to TNF modulates the utilization of two important
energy sources, fat and protein (254), it may be reasonable to suspect
that TNF also interferes with the regulation of the third energy
substrate, glucose.
The hyperlactacidemia which accompanies endotoxicosis (137,187,
282) may be mediated, in part, by endogenous TNF (16,249,253).

Since the

hyperlactacidemia induced by low and high dose ETX was significantly
earlier than that elicited by high dose TNF, it suggests that the initial
increase in plasma lactate probably is not mediated by endogenous TNF
activity.

The initial rise

i~

plasma lactate observed after ETX

administration probably results from the increased availability of
glucose under conditions of hypoperfusion or hypoxia due to the ETXinduced hypotension.

However, the progressive elevation in plasma
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lactate observed subsequent to high dose TNF administration suggests that
TNF is more likely involved in the persistant elevation in plasma lactate
observed after ETX administration.

The progressive hyperlactacidemia

which develops after TNF admir.istration probably is the result of TNFinduced tissue hypoxia.

TNF-induced endothelial cell procoagulant

activity (29,186) and endothelial cell disruption (242) compromise organ
blood flow and oxygen delivery, which leads to an elevation in plasma
lactate concentrations and organ damage.
Thus, the comparison between the metabolic changes observed during
endotoxicosis to those induced by TNF showed the following:

1) endo-

genous TNF most likely is not involved in the initial hyperglycemia
observed after ETX administration, although it may participate in
maintaining plasma glucose concentrations at elevated levels; 2) endogenous TNF activity is more likely to participate in eliciting the
profound hypoglycemia observed late in the course of endotoxicosis; and
3) endogenous TNF activity contributes to the hyperlactacidemia observed
during the latter stages of endotoxicosis as a result of TNF-induced
tissue hypoxia.
4.

Neuro-endocrine comparisons:

alterations in plasma insulin,

catecholamines, and corticosterone
The hormonal changes observed after TNF and ETX administration
strongly support the role of TNF as a mediator of these endocrine
alterations.

The hypoinsulinemia observed

~

ite after ETX administration,

as reported here and by Kelleher, et al. (123), may result from the
accompanying hypoglycemia.

However, as observed in this study, the

magnitude of the hypoinsulinemic responses induced by ETX and TNF were

144
larger than warranted based on the accompanying plasma glucose concentrations, thus suggesting that TNF may contribute to the severity of
the hypoinsulinemia of sepsis.

This conclusion is supported not only by

the in vivo comparison, but also by the in vitro studies which demonstrated that TNF reduced insulin secretion by 40% (18) without damaging
islet integrity (153) or insulin content (18).
Additionally, although not dramacically demonstrated in this
study, a significant basal hyperinsulinemia usually occurs within the
first 90 minutes after ETX administration (35,117,123) as a result of
pancreatic hypersecretion (283).

TNF also may contribute to the hyper-

insulinemia of endotoxicosis, as demonstrated by the slight increase in
plasma insulin concentrations reported after high dose TNF (figures 13
and 14) and by the 3 fold increase in plasma insulin reported by Bagby,
et al. (13).

Their conclusions, however, are limited since the pre-

injection control insulin concentrations were not reported.

While the

data supporting the role of TNF in the hypoinsulinemia of endotoxic shock
is credible, further studies need to be done in order to ascertain the
ability of TNF to modulate the hyperinsulinemic response observed early
during endotoxicosis.
The elevations in plasma epinephrine and norepinephrine concentrations induced by exogenous TNF suggest that TNF partially mediates
the increase in plasma catecholamine concentrations reported during
endotoxicosis.

Although the effects of ETX on plasma catecholamines were

not evaluated in this study, Jones and Romano (116) documented the
changes in conscious, cannulated rats:

plasma epinephrine and nor-

epinephrine concentrations increased dramatically within the first 30
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minutes after the bolus injection of ETX and remained significantly
elevated for 360 minutes.

The initial elevation in plasma catecholamine

levels coincided with the hypotensive effect of ETX, thereby suggesting
that the initial elevations in plasma epinephrine and norepinephrine were
a reflex response to the ETX-induced hypotension.

However, plasma

catecholamine concentrations remained elevated for 360 minutes, which was
long after the mean blood pressure had returned to control levels at 120
minutes.

In light of the increase in plasma catecholamine concentrations

induced by exogenous TNF administration both in this study and in studies
performed by other investigators (13,253), the persistant elevation in
plasma epinephrine and norepinephrine observed during endotoxicosis may
result from endogenous TNF activity.

Although the mechanism responsible

for the TNF-induced elevation in plasma catecholamine concentrations is
unknown, there are three possible explanations for this finding.

First,

TNF may increase sympathetic activity by acting directly on the hypothalamus to increase sympathetic outflow.

Second, TNF may increase

circulating levels of plasma catecholamines by interfering with
peripheral sympathetic activity.

TNF may directly increase nor-

epinephrine release at the nerve terminals and/or interfere with norepinephrine reuptake and degradation.

Third, the elevation in plasma

epinephrine, primarily, may result from TNF-stimulated release from the
adrenal medulla.
in

th'~

Even though TNF's mechanism of action was not examined

study, the findings suggest that the elevated catecholamine

concentrations observed during endotoxicosis may result from two stimuli:
l) an initial baroreceptor reflex response to the ETX induced hypotension
resulting in the immediate elevation in plasma catecholamine concentra-
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tion; and 2) endogenous TNF induced increase in plasma epinephrine and
norepinephrine by, as yet, an unknown mechanism.
Finally, elevation in the stress hormone corticosterone during
endotoxicosis may result from endogenous TNF activity.

Although it was

not determined in this study, plasma corticosterone concentrations are
generally increased during endotoxicosis (107,123):
in~Lease

plasma levels

approximately 45% two hours after a bolus injection of ETX.

As

shown in this study and in other studies (253,276), TNF induced a
significant increase in plasma corticosterone concentrations within 30
minutes.

This may have resulted directly from a stimulatory effect of

TNF on the adrenal glands or indirectly by TNF increasing plasma
adrenocorticotrophic hormone levels (174,175).

The time course for the

elevation in plasma corticosterone concentrations observed after ETX
administration compared to the response elicited with exogenous TNF
suggests that endogenous TNF produced in

~esponse

to an ETX challenge may

mediate the increase in plasma corticosterone reported during endotoxicosis.
These observations indicate that TNF may be a primary mediator of
the following neuro-endocrine alterations observed during endotoxic
shock:

1) hypoinsulinemia; 2) persistant elevation of plasma epinephrine

and norepinephrine; and 3) elevated corticosterone concentrations.
5.

Additional pathophysiological effects
In addition to the lethal, hemodynamic, metabolic, and neuro-

endocrine effects examined in this study, TNF may mediate some additional
pathophysiological changes observed during endotoxicosis, such as:

fever

(31,66,126,154,156,276); stimulation of acute phase protein synthesis
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(59,151,178,181,199,236,276); muscle protein degradation (276); depressed
plasma iron concentrations (175); complement activation (181);

increased

procoagulant activity (29,186); decreased lipogenesis (194,196,248); and
PMN infiltration (58,176,229).

Exogenous TNF also induced histological

changes in the lungs, liver, kidneys, and gastrointestinal tract which
were similar to those observed during endotoxicosis, such as PMN
infiltration,

fv~al

areas of necrosis, and vascular congestion (personal

observations) (88,195,210,249,253,254).

All these changes induced by TNF

administration alone further support the belief that endogenous TNF
activity is a primary mediator of pathophysiological changes observed
during septic shock.
6.

Other mediators and interactions
Significant concentrations of TNF are measurable not only after

ETX challenge, but also during bacterial meningitis (147), visceral
leishma~iasis

(227), malaria (227), meningococcal meningitis, septicemia,

or both meningitis and septicemia (269).

As discussed previously, there

appears to be a positive correlation between the severity of the insult
and the amount of TNF detected (103 224).
1

However, detection of plasma

TNF alone is not enough to determine the severity of the insult
(127,179), therefore suggesting that additional inflammatory mediators
may be just as important in the progression of lethal infections (103).
One such mediator, interleukin 1, might have an important role in the
pathophysiology observed after TNF and ETX administration.

TNF

stimulates IL-1 production and release both in y:iyQ (66) and in vitro
(12,62,150,185,202) as does ETX (57,65).

As reviewed by Dinarello (65),

IL-1 mediates many of the responses prevalent during inflammation such
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as fever, neutrophilia, alterations in plasma divalent cations, synthesis
of acute phase proteins, stimulation of muscle proteolysis, and stimulation of B and T cell function.

IL-1 also induces hypoglycemia (63,104)

and enhances the rate of glucose clearance after a glucose challenge
(219).

Endocrine alterations resulting from IL-1 administration include

hyperinsulinemia (63,219), hyperglucagonemia (63) and elevated serum
corticosterone levels (213).

These findings suggest that endogenous IL-1

may be an important mediator in both ETX- and TNF-induced shock, since
many of the pathophysiological changes observed after ETX and TNF
administration can also be produced by IL-1.
More importantly, perhaps, may be the interaction between TNF and
IL-1.

IL-1 increases the lethal effects of TNF (268):

the LD50 dose for

TNF is reduced 3 fold when administered in conjunction with a non-lethal
dose of IL-1.

The shock-like (190) and lethal effects (268) observed

after co-treatment with TNF and IL-1 were more than additive.

Further-

more, TNF and IL-1 synergize in stimulating PMN infiltration (274), islet
cell destruction (206), and tumor cell cytostasis (192).
Other mediators, such as arachidonic acid metabolites, oxygen
derived free radicals, and platelet activating factor, also may
contribute to the pathogenesis of TNF and ETX.

Prostaglandin E2 and

prostacyclin production and release are stimulated by TNF (12,61,120,
125,182) and ETX (84,124,144) and may mediate the fever, glucose alterations, gastrointestinal dam

~a,

and mortality observed after either

agent (66,84,124,125,144,182,235,247).

Oxygen derived free radicals

released from infiltrating PMNs in response to TNF (11,140,166,260,277)
and ETX (84) challenge contribute to the tissue damage elicited by each
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agent.

Platelet-activating factor, likewise, is released in response to

TNF (38,245) and ETX (44,99,138,271) and may contribute to the hemodynamic changes as well as the tissue injury demonstrated after their
administration.

Furthermore, macrophage released mediators such as

macrophage insulin-like activity (74,284) and macrophage insulin releasing activity (79) may be important in mediating the glucose and
endocrine alterations observed during endotoxicosis.
IFN-~

is also involved in the pathogenesis of endotoxicosis.

It

is released after ETX stimulation (264) and subsequently increases TNF
production (27,36,52,91,92) and TNF binding sites (5,217,257,259).
Moreover,

IFN-~

synergizes with TNF in causing mortality (247), cyto-

toxicity (45,244), and tissue damage to organs such as liver, lung,
gastrointestinal tract, spleen, and uterus (247).
production of TNF, IL-1, and

IFN-~

The sequential

in response to an ETX or bacterial

challenge may be crucial in the development of irreversible shock (103):
all three mediators are produced sequentially after a lethal bacterial
challenge, whereas only TNF and IL-1 are sequentially produced after a
non-lethal endotoxin challenge.
C.

IN VIVO EFFECTS OF TNF PLUS ETX CO-TREATMENT
1.

Mortality and morbidity
A further assessment of TNF as a mediator of endotoxic shock was

performed using a co-treatment model to determine whether low doses of
each agent given within seconds of each other \'ould produce a highly
lethal shock-like effect similar to that observed after challenge with
highly lethal doses of either agent given alone.

In this study, the

effects of TNF plus ETX co-treatment on mortality, hemodynamic,
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metabolic, and endocrine parameters were evaluated.

As reported in this

study and by Rothstein and Schreiber (214), exogenous TNF plus exogenous
ETX co-treatment produces a highly lethal response within a matter of
hours.

TNF not only synergizes with exogenous ETX (214), but also

enhances the lethal effects of endogenous bacteria released subsequent to
cecal ligation and puncture (263).
The enhanced lethality observed after TNF plus ETX co-treatment
may be mediated by the dual elevations in plasma TNF concentrations
produced in response to both agents.

As demonstrated by Mathison, et al.

(161), infusion of exogenous TNF followed by a bolus injection of ETX
produced 2 peaks in blood TNF concentrations:

the initial peak cor-

responded to the infused exogenous TNF and the second peak corresponded
to endogenous TNF production and release in response to the ETX
challenge.

This response is unique to stimulation with TNF and ETX, for

repeated stimulation with a single agent, such as ETX or TNF, did not
produce such a response.

Stimulation with repeated doses of ETX (90,161)

or repeated doses of TNF (272) failed to elicit repeated elevations in
plasma TNF concentration.

Macrophages produce a limited quantity of TNF

in response to ETX challenge, therefore repeated stimulation with ETX
does not increase the amount of TNF produced (25,81,90,91).

The

inability to repeatedly elevate plasma TNF concentrations may be the
basis for the desensitization which occurs relative to the respective
stimulus.
The synergism observed between TNF and ETX may be a major
component in the pathophysiology of TNF- and ETX-induced shock.

Sig-

nificant gastrointestinal damage is induced by both agents, which may
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result in the release of gut-derived bacteria and endotoxin.
turn, may exacerbate the condition in two ways.

This, in

First, the gut-derived

bacteria and ETX can synergize with circulating TNF, thus augmenting the
mortality and pathophysiological changes elicited by each agent.

Se-

condly, the gut-derived bacteria and ETX may stimulate the macrophages to
release TNF, thereby maintaining or further increasing circulating levels
of TNF.

Moreover, ETX interacts with the macrophages, perhaps through

the myristoylation of macrophage receptors (2,3), and increases intracellular protein kinase C levels (218,279).

Elevation of intracellular

protein kinase C stimulates TNF mRNA production (102) as well as reduces
TNF receptor binding (4,109,115,262), thereby further increasing circulating levels of TNF.

Low concentrations of circulating TNF appear to

have beneficial effects which destroy invasive agents and protect the
host.

However, it appears that extremely high concentrations of TNF

and/or prolonged elevation of TNF may mediate the eventual demise of the
host.
2.

Hemodynamic, metabolic, and endocrine effects
The hemodynamic, metabolic, and endocrine changes induced by TNF

plus ETX co-treatment were evaluated with the expectation that they might
provide some insight in how these agents combine to produce a highly
lethal shock-like effect.

TNF plus ETX co-treatment may compromise

cardiac function, as evidenced by the failure to elicit a significant
tachycardia in response to the significant hypotension observed 30
minutes afer TNF plus ETX co-treatment.

Highly lethal doses of either

TNF or ETX induced significant elevations in heart rate even though high
dose TNF did not induce an initial hypotension.

However, co-treatment

152
prevented such a response, suggesting that ETX plus TNF together may be
directly toxic to the heart or that the reflex stimulation of catecholamine release was somehow compromised.

However, since plasma

epinephrine and norepinephrine levels were not determined for the TNF
plus ETX co-treated animals, these suggestions are all speculative.
The possibility that TNF plus ETX co-treatment compromises cardiac
function is supported by the greater degree of hyperlactacidemia produced
after co-treatment than produced after treatment with high doses of
either agent alone.

Elevated lactate concentrations are indicative of

anaerobic u.etabolism due to inadequate oxygen supply.

Insufficient

oxygen delivery to the vital organs may result from inadequate cardiac
function and/or inadequate blood flow due to enhanced procoagulant
activity.
The delayed increase in insulin secretion relative to the hyperglycemia observed after TNF plus ETX co-treatment indicates that the
responsiveness of the islets to a glucose stimulus was compromised or
that the blood supply to the pancreas was altered.

Normally, insulin

levels increase in less than 10 minutes after a glucose stimulus (96),
whereas after TNF plus ETX co-treatment, 60 minutes passed before a
significant hyperinsulinemia was elicited in response to the hyperglycemic stimulus.
The lethal hypoglycemia observed after treatment with high doses
of TNF or ETX alone was also induced in the TNF plus ETX co-treated

rat~.

The hypoglycemia accompanying the death of the rats occurred earlier, as
evidenced by the 100% mortality rate in 4 hours.

These extremely low

plasma glucose concentrations suggest that the fuel delivery to the vital
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organs was probably inadequate to meet metabolic demands and therefore
contributed to the demise of the animals.
The enhanced lethality and pathophysiological changes induced by
TNF plus ETX co-treatment may be caused not only by the dual elevation in
plasma TNF levels butt also by additional mediators known to be released
in response to TNF and ETX.
at various

concenL~ations

Perhaps it is the combination of mediators

which induce irreversible shock since TNF

synergizes with ETX, IL-1 and

IFN-~.

Experiments with "mediator

cocktails" analogous to Coley's cocktails may provide some important
insights.

By controlliitg the levels of a particular mediator in question

with specific antibodies, the mediator cocktails can be given in the
hopes of

ascertaini~g

which mediators at what concentrations are required

to induce a shock like state.
C.

IN VITRO EFFECTS OF TNF ON HEPATIC GLUCOREGULATION
The in vivo changes induced by exogenous TNF suggested that it may

actively mediate some of the pathophysiological changes in plasma glucose
and lactate concentrations observed during endotoxic shock.
liver functions as the major

produc~r

Because the

of plasma glucose, TNF was tested

in vitro for direct hepatic glucoregulatory activity using two in vitro
models:

isolated perfused rat livers and isolated liver cells.

The

perfused rat liver model was used to examine the direct effects of TNF on
whole organ function vis-a-vis alterations in net glucose and lactate
production, oxygen consumption, and organ perfusion.
of hepatic function would demonstrate:

This in vitro model

1) if TNF altered plasma glucose

and lactate production by interfering with organ blood flow via changes
in vascular resistance; and 2) if TNF influenced hepatic glucose and
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lactate production by stimulating mediator release, such as prostaglandins, from the lining endothelial and Kupffer cells (48,93).

The

isolated hepatocytes demonstrated only the direct effects of TNF on
parenchymal cAll glucose and lactate production, since the preparations
were virtually devoid of contaminating non-parenchymal cells.

Together,

these two in vitro models would ascertain whether or not TNF influences
hepatic glucoregulation and if the response was a direct TNF-induced
alteration in hepatocyte glucogenesis or a secondary response due to TNFinduced mediator release and/or vascular tone alteration.
The direct hepatic glucoregulatory effect of TNF was initially
examined using the isolated perfused rat liver model.

Initial exogenous

TNF concentrations in the perfusate were comparable to plasma TNF
concentrations found circulating in vivo after a lethal ETX challenge.
Exogenous TNF failed to modulate net glucose production by isolated
perfused livers, suggesting that the slight hyperglycemia observed after
TNF administration was not due to TNF-stimulated hepatic glucose
production.

If TNF either directly stimulated liver glucose production

or indirectly stimulated glucose production through the production of
prostaglandins, changes in net glucose production by the isolated
perfused rat livers would have occurred within the time frame of the
perfusions (148).

Furthermore, the slight hyperglycemia observed after

TNF administration was not stimulated by TNF-induced hepatic hypoperfusion or inadequate oxygen cons-1. .rnption since such alterations in flow
1

rate and oxygen consumption were not demonstrated with the isolated
perfused livers.
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When applied to the ETX model of septic shock, these in vitro
observations suggest that endogenous TNF probably is not directly
responsible for the hyperglycemia observed shortly after ETX
administration.

However, our in&bility to directly stimulate glucose

production in vitro with ETX using isolated perfused livers suggested
that a mediator was responsible for the hyperglycemic effect of ETX (data
not shown).

Only one study conducted by Casteleijn, et al. (42) de-

monstrated a direct glycogenolytic effect of ETX using perfused livers.
The perfusion flow rate, however, was insufficient for adequate oxygen
delivery to the perfused livers, thus implying that the perfused livers
in their study were hypoxic.

The data in this study proposes that the

hyperglycemia observed during ETX- and TNF-induced shock is

m~diated

at

least in part by the elevated catecholamine levels produced indirectly by
the reflex response to ETX-induced hypotension and directly by the
administration of exogenous TNF.

The elevated corticosterone levels

observed at 2 hours and 30 minutes after ETX and TNF challenge,
respectively, also contributed to the plasma glucose concentration by
stimulating glucose production by the liver.
The hypothesis that a hepatic action of TNF may be responsible for
mediating the hypoglycemia observed late in the course of ETX- and TNFinduced shock is not supported by the perfused liver data.

TNF failed to

significantly reduce net glucose production rate under both basal and
glucagon-stimulated conditions.

If TNF directl; prevented the mobil-

ization of glucose or interfered with glucose mobilization in response to
hormone stimulation, then the perfused liver model would have demonstrated such a response.

Perhaps, longer treatment with TNF is required
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to elicit such an effect, since treatment with TNF for more than 12 hours
was required to demonstrate a direct in vitro effect of TNF on hepatic
protein synthesis (59,151,181,199).

Additionally, other mediators re-

leased by TNF and ETX administration may be involved in the hypoglycemia.
For instance, a significant hypoglycemic response was demonstrated after
IL-1 administration (63,104), but preliminary studies from this
laboratory failed to demonstrate a direct glucoregulatory effect of IL-1
on perfused rat livers.
The hyperlactacidemia observed after ETX and TNF administration
suggested that TNF may be responsible for the hyperlactacidemia of septic
shock.

When examined using perfused rat livers, TNF did not induce any

changes in hepatic lactate production under basal or hormone stimulated
conditions, thus suggesting that the elevated lactate concentrations
observed after TNF and ETX treatment were not produced as a result of
altered hepatic function.
observations.

This hypothesis is supported by the following

First, TNF did not directly stimulate lactate production

by the perfused rat livers, indicating that the hyperlactacidemic effect
of TNF was not the result of enhanced basal lactate production by the
liver.

Second, TNF did not interfere with glucagon-stimulated hepatic

uptake of lactate, suggesting that the gluconeogenic ability of the liver
was not compromised by treatment with TNF.

Third, TNF did not stimulate

lactate production by altering hepatic perfusion flow or oxygen consumption, thus suggesting that liver function is not compromised by TNF
treatment in a blood-free media.

However, since the livers were perfused

with a KRB media and not with whole blood, this system was devoid of the
procoagulant activity induced by TNF (29,186).

Since TNF strongly
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stimulates blood coagulation, our data suggests that the hyperlactacidemia observed during TNF- and ETX-induced shock probably resulted
from tissue hypoxia due to inadequate oxygen delivery rather than a
direct TNF-induced alteration in liver function.
In order to assure that the results obtained using the perfused
liver model were a true indication of the short term effects of TNF on
hepatic function, isolated liver parenchymal cells were challenged with
TNF directly.

In this manner, the initial concentration of TNF directly

stimulating the hepatic parenchymal cells was dependent on the concentration of TNF in the incubation medium.

Unlike the perfused liver

model, these isolated cell preparations were virtually devoid of contaminating non-parenchymal cells such as endothelial and Kupffer cells
which may interfere with the concentration of TNF directly in contact
with the parenchymal cells.

Since the concentration of TNF directly in

contact with hepatocytes after ETX stimulation in vivo has not been
determined, this model allowed for a range of TNF concentrations to be
tested directly.

Isolated hepatocytes were incubated directly with TNF,

at concentrations ranging from 0.01 to 5.0 µg/ml.

In agreement with the

isolated perfused liver data reported in this study and the isolated
hepatocyte data of Rofe, et al. (212), TNF did not enhance the basal
glucose production by isolated hepatocytes.

Thus, the hyperglycemia

induced with TNF does not result from a direct hepatic action of TNF.
Instead, th

0

hyperglycemia observed during TNF- and ETX-induced shock is

most likely mediated by the elevated catcholamine as well as corticosterone levels, as discussed previously.
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TNF also did not interfere with hormone-stimulated glucose
production using two glucogenic hormones; glucagon and vasopressin.
Glucagon and vasopressin stimulate glucose production via two different
intracellular mechanisms:

glucagon stimulates hepatic glucose production

by a cAMP-dependent mechanism whereas

~asopressin

production by a ca++-dependent mechanism.

stimulates glucose

TNF did not interfere with the

ability of either hormone to stimulate hepatic glucose production, supporting the hypothesis that TNF-treatment does not alter the intracellular second messengers involved in hepatic glucose production.
TNF not only failed to influence basal and hormone-stimulated
glucose production, but also failed to alter the gluconeogenic capability
of the liver as assessed by net glucose production (212).

Although not

shown in this dissertation, TNF at concentrations of 0.01-5 µg/ml did not
alter the gluconeogenic capability of isolated hepatocytes.

A similar

finding was demonstrated by the depressed lactate production observed
with glucagon-stimulated hepatocytes.

TNF did not inhibit the uptake of

the gluconeogenic substrate lactate by the isolated hepatocytes
stimulated with the gluconeogenic-stimulatory hormone, glucagon.

Thus,

this data supports the hypothesis that the hypoglycemia observed during
the agonal stages of TNF- and ETX-induced shock was not mediated by a
direct TNF-induced inhibition of hepatic gluconeogenesis.

Furthermore,

increased hepatic glucose utilization by the parenchymal cells of the
liver does not seem to be involved in the hypoglycemia induced by TNF and
ETX since TNF failed to directly enhance glucose utilization by isolated
hepatocytes in vitro.

Perhaps, as proposed by Meszaros, et al. (173),

enhanced glucose utilization by the macrophage-rich organs may contribute
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to the hypoglycemia of TNF- and ETX-induced shock.

Since glucose

utilization by the isolated perfused liver was not assessed in this
study, that may be a direct hepatic effect of TNF.

Additional studies

evaluating the role of TNF on hepatic glucoregulation may require longer
treatment with TNF or more sensitive indices of altered hepatic function
such as changes in key glucoregulatory enzyme levels and activity.
The in vitro data obtained using isolated perfused rat livers and
isolated liver parenchymal cells suggests that TNF does not mediate the
hyper- and hypoglycemia observed during TNF- and ETX-induced shock by
directly altering hepatic glucoregulation.

However, previous studies

from this laboratory (76) demonstrated that the glucoregulatory changes
observed during end9toxic shock could not be reproduced in vitro using
isolated hepatocytes stimulated with ETX.

Therefore, mediators released

from the sinusoidal Kupffer cells were proposed to be responsible for the
glucoregulatory changes observed after ETX administration (41,171).

In

light of the results reported in this study and by Rofe et al. (212), the
search for a direct hepatic glucoregulatory mediator is not over.

Ad-

ditional in vitro studies using a n1,l1Ilber of important inflammatory
mediators such as IL-1,

IFN-~.

and TNF, as well as the development of

techniques to measure the concentrations of inflammatory mediators in
contact with hepatic parenchymal cells in vivo, may provide further data
concerning the role of inflarnmtory mediators in hepatic glucoregulation.

CHAPTER VI
SUMMARY AND CONCLUSIONS
Thts study examined the role of TNF in the pathophysioJogy of septic
shock.

In specific, the role of TNF as an important mediator of the

endotoxic syndrome was evaluated in three ways.

First, the hemodynamic,

metabolic, and endocrine alterations induced by bolus injections of

E~X

were compared to the hemodynamic, metabolic, and neuro-endocrine alterations induced by comparably lethal injections of TNF using conscious,
unrestrained, cannulated, adult rats.

Second, the lethal, hemodynamic,

metabolic, and endocrine alterations induced by the co-administration of
low doses of TNF plus ETX were examined.

Third, the direct gluco-

regulatory effects of TNF on liver glucose and lactate production were
examined using two different in vitro models -- isolated perfused rat
livers and isolated liver parenchymal cells.

The following conclusions

were derived from the data in this study.

1) TNF induced a dose-dependent, lethal, shock-like

stat~

in

conscious, unrestrained, cannulated rats similar to that induced by ETX.
2) The morbidity induced after TNF administration was identical to
that induced after ETX administration:

rats exhibited such signs as

piloerection, hunched-over posture, labored breathing, and progressive
cyanosis.
3) The initial hypotension induced after ETX ac: ..1inistration was not
mediated by endogenous TNF activity, for exogenous TNF did not induce any
significant changes in mean blood pressure.
160
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4) Endogenous TNF may mediate the prolonged elevation in heart rate
observed after the mean blood pressure returned to control values
following the hypotensive response to ETX administration:
exogenous TNF induced a progressive

i~crease

high dose

in pulse rate.

5) The elevated pulse rates observed after TNF administration may be
a secondary response due to the elevation in plasma epinephrine and
norepinephrine concentrations induced by TNF.
6) Both TNF and ETX induced a hyperglycemic response.

However, the

hyperglycemia observed after ETX and TNF administration did not result
from a direct hepatic effect of TNF, as evidenced from the inability to
demonstrate an increase in the net glucose production rates by isolated
perfused livers and isolated hepatocytes treated with TNF in vitr..Q.
7) The hyperglycemia induced after ETX and TNF administration was
probably mediated by the elevated catecholamine and corticosterone
concentrations observed following ETX and TNF administration.
8) Both TNF and ETX elicited a profound hypoglycemia coincident with
the death of the rats.

The hypoglycemia observed during the agonal

stages of TNF- and ETX-induced shock was probably not mediated by a
direct effect of TNF on hepatic function:

TNF did not interfere with the

net glucose production rates of isolated perfused livers or isolated
liver cells.
9) Endogenous TNF activity may contribute to the hyperlactacidemia
that developed after ETX administration, for a prc.;::'essive hyper
lactacidemia developed subsequent to exogenous TNF administration.
10) Tissue hypoxia and organ damage which develop as a result of TNFinduced procoagulant activity and vascular disruption may be responsible
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for the hyperlactacidemia observed after TNF and ETX administration.
11) TNF may mediate the hyperinsulinemia reported during endotoxicosis.
12) The hypoinsulinemia observed after TNF administration suggested
that TNF may be responsible for the hypoinsulinemia observed during the
latter stages of endotoxicosis by reducing insulin release in response to
a glucose stimulus.
13) Endogenous TNF-induced elevation in plasma epinephrine and norepinephrine concentrations may contribute to the persistant elevation in
plasma catecholamines observed during endotoxicosis after the mean blood
pressure returned to control values.

Exogenous TNF induced a progressive

increase in plasma epinephrine and norepiniephrine concentrations by
acting centrally, peripherally, or on the adrenal medulla to increase the
circulating concentrations of catecholamines.
14) Endogenous TNF may mediate the elevation in plasma corticosterone
concentrations observed after ETX administration:

exogenous TNF induced

a significant elevation in plasma corticosterone.
15) Co-treatment with low doses of TNF plus ETX augmented the lethal
effects of both agents.
16) The mechanism responsible for the enhanced lethality observed
after co-treatment with low doses of TNF plus ETX remains to be determined, however, compromised cardiac function may be a possibility.
17) TNF does not directly influence short-term hepatic glyogenolysis,
gluconeogenesis, or glucose utilization under both basal and hormonestimulated conditions

vitro.
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18) TNF does not directly interfere with in vitro liver perfusion
flow or oxygen consumption.
Figure 19 is a schematic representation of TNF's role in the
pathogenesis of septic shock, as caused by invading gram negative bacteria and its constituent ETX.

TNF is surely an important mediator of

the hemodynamic, metabolic, and neuro-endocrine alterations associated
with septic shock.

However, to conclude that TNF is the major mediator

of the lethal effects of septic shock would be naive in light of the
other inflammatory mediators known to be released and to interact with
TNF, such as IL-1 and IFN-7.

Moreover, the interaction between TNF and

ETX suggests that the organ pathology induced in vivo, in particular the
hemorrhagic necrosis of the gastrointestinal tract, may be a crucial
factor contributing to the lethal demise of the host.
Further studies examining the role of inflammatory mediators in the
pathophysiology accompanying gram negative bacterial infection may provide helpful insights into the sequence of events which are responsible
for causing a gram negative infection to progress to a lethal state of
septic shock.

In this way, therapeutic intervention can be better

directed toward the lethal agent(s) and thus decrease the mortality
associated with this modern day health problem.

FIGURE 19:

TUMOR NECROSIS FACTOR AND THE PATHOPHYSIOLOGV .OF SEPTIC SHOCK
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